Cancer treatment combinations
A combination of BTK antagonists and anti-ROR-1 antibodies targets Wnt5a-induced Rac1 activation in CLL, overcoming resistance to BCR inhibitors like ibrutinib, thereby enhancing treatment efficacy against chronic lymphocytic leukemia.
Patent Information
- Application Number
- JP2024127673
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-06-27
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for chronic lymphocytic leukemia (CLL) using B-cell receptor (BCR) inhibitors like ibrutinib face challenges in eradicating the disease and preventing recurrence, particularly due to the activation of signaling pathways such as Wnt5a-induced Rac1 activation that counteract the therapeutic effects.
A combination therapy involving a Bruton's tyrosine kinase (BTK) antagonist and a tyrosine kinase-like orphan receptor 1 (ROR-1) antagonist, such as anti-ROR-1 antibodies, is used to inhibit Wnt5a-induced Rac1 activation in CLL cells, enhancing the efficacy of BCR inhibitors like ibrutinib.
The combination therapy effectively inhibits Wnt5a-induced proliferation and engraftment of CLL cells, leading to improved treatment outcomes by synergistically targeting key signaling pathways that resist single-agent BCR inhibitor treatments.
Smart Images

Figure 2024156869000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 355,171, filed June 27, 2016, which is incorporated by reference in its entirety for all purposes.
[0002] Reference to a "sequence listing", table or computer program listing attachment submitted as an ASCII file The sequence listing in file 48537-582001WO SL_ST25.TXT, created on June 19, 2017 (10,919 bytes, machine format IBM-PC, MS-Windows operating system) is incorporated herein by reference.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under Grant No. CA081534 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]
[0004] Signal transduction through BCR (B cell receptor) signaling is believed to play a role in the pathogenesis and / or progression of diseases, such as chronic lymphocytic leukemia (CLL). Furthermore, agents targeting B cell receptor (BCR) signaling in lymphoid and leukemia malignancies, including ibrutinib and acalabrutinib (4-{8-amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide), which inhibit Bruton's tyrosine kinase (BTK), have shown remarkable clinical activity. By disrupting the B cell signaling pathway, BTK therapy is accompanied by dramatic lymph node responses, but eradication of disease and recurrence of high-risk disease remain a challenge. Summary of the Invention [Problem to be solved by the invention]
[0005] Solutions to these and other problems in the art are provided herein. [Means for solving the problem]
[0006] The compositions and methods provided herein are particularly useful for treating leukemia. For example, surprisingly, an effective method is provided for using a combination of an anti-ROR-1 antibody and a BCR inhibitor to treat chronic lymphocytic leukemia (CLL).
[0007] In certain aspects, methods of treating cancer in a subject in need of treatment are provided, comprising administering to the subject therapeutically effective amounts of a Bruton's tyrosine kinase (BTK) antagonist and a tyrosine kinase-like orphan receptor 1 (ROR-1) antagonist.
[0008] In one embodiment, a pharmaceutical composition is provided that includes a BTK antagonist, a ROR-1 antagonist, and a pharma- ceutically acceptable excipient.
[0009] In one aspect, a pharmaceutical composition is provided that includes a BTK antagonist, an anti-ROR-1 antibody, and a pharma- ceutically acceptable excipient, wherein the BTK antagonist and the anti-ROR-1 antibody are present in a combined, synergistic amount, and the combined, synergistic amount is effective to treat cancer in a subject in need of such treatment.
[0010] In one embodiment, a method of treating cancer in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and an anti-ROR-1 antibody.
[0011] In another aspect, a pharmaceutical composition is provided that includes a Bruton's tyrosine kinase (BTK) antagonist, an anti-ROR-1 antibody, and a pharma- ceutically acceptable excipient. [Brief description of the drawings]
[0012] [Figure 1A] Figures 1A-1D. UC-961 inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 1A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with UC-961 or ibrutinib as indicated at the top of each lane. (Figure 1B) Wnt5a-induced Rac1 activation in untreated CLL cells or CLL cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (Figure 1C) CLL cells were collected from an ibrutinib-treated patient (n=5). Active Rac1 was measured in these CLL cells treated in vitro with or without Wnt5a or UC-961 as indicated at the top of each lane. (FIG. 1D) Rac1 activation was measured in CLL cells collected from patients treated with ibrutinib and treated with Wnt5a and / or UC-961. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 1B]Figures 1A-1D. UC-961 inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 1A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with UC-961 or ibrutinib as indicated at the top of each lane. (Figure 1B) Wnt5a-induced Rac1 activation in untreated CLL cells or CLL cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (Figure 1C) CLL cells were collected from an ibrutinib-treated patient (n=5). Active Rac1 was measured in these CLL cells treated in vitro with or without Wnt5a or UC-961 as indicated at the top of each lane. (FIG. 1D) Rac1 activation was measured in CLL cells collected from patients treated with ibrutinib and treated with Wnt5a and / or UC-961. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 1C]Figures 1A-1D. UC-961 inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 1A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with UC-961 or ibrutinib as indicated at the top of each lane. (Figure 1B) Wnt5a-induced Rac1 activation in untreated CLL cells or CLL cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (Figure 1C) CLL cells were collected from an ibrutinib-treated patient (n=5). Active Rac1 was measured in these CLL cells treated in vitro with or without Wnt5a or UC-961 as indicated at the top of each lane. (FIG. 1D) Rac1 activation was measured in CLL cells collected from patients treated with ibrutinib and treated with Wnt5a and / or UC-961. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 1D]Figures 1A-1D. UC-961 inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 1A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with UC-961 or ibrutinib as indicated at the top of each lane. (Figure 1B) Wnt5a-induced Rac1 activation in untreated CLL cells or CLL cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (Figure 1C) CLL cells were collected from an ibrutinib-treated patient (n=5). Active Rac1 was measured in these CLL cells treated in vitro with or without Wnt5a or UC-961 as indicated at the top of each lane. (FIG. 1D) Rac1 activation was measured in CLL cells collected from patients treated with ibrutinib and treated with Wnt5a and / or UC-961. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 2A] Figures 2A-2B. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 2A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative CLL sample is shown along with the cell division rate. (Figure 2B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of six different patients for each culture condition shown at the bottom. Data are presented as mean ± SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 2B] Figures 2A-2B. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 2A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative CLL sample is shown along with the cell division rate. (Figure 2B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of the six different patients for each culture condition shown at the bottom. Data are presented as mean ± SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Diagram 3] Figure 3. Additive inhibitory effect of UC-961 and ibrutinib in xenografted mice derived from CLL patients. CLL cells were injected into the peritoneal cavity of Rag2- / -γc- / - mice one day before the indicated treatment. Peritoneal lavage fluid was collected 7 days after cell injection and residual CLL was determined by cell counting and flow cytometric analysis after staining with mAbs specific for CD5, CD19 and CD45. Each bar on the graph represents the percentage of residual CLL cells collected from treated mice normalized to cells collected from untreated mice. Data shown are the mean ± SEM with 5 mice in each group from 3 different patients. P values were calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 4A]Figures 4A-4D. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 4A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a as indicated at the top of each lane and treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The numbers below each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to the untreated sample. (Figure 4B) Wnt5a-induced Rac1 activation was measured in untreated ROR-1 x TCL1 leukemia cells or ROR-1 x TCL1 leukemia cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 4C) CD154-induced proliferation of CFSE-labeled ROR-1×TCL1 leukemia cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative ROR-1×TCL1 leukemia cell sample is shown together with the cell division rate. (FIG. 4D) Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 4B]Figures 4A-4D. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 4A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a as indicated at the top of each lane and treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The numbers below each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to the untreated sample. (Figure 4B) Wnt5a-induced Rac1 activation was measured in untreated ROR-1 x TCL1 leukemia cells or ROR-1 x TCL1 leukemia cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 4C) CD154-induced proliferation of CFSE-labeled ROR-1×TCL1 leukemia cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative ROR-1×TCL1 leukemia cell sample is shown together with the cell division rate. (FIG. 4D) Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 4C]Figures 4A-4D. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 4A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a as indicated at the top of each lane and treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The numbers below each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to the untreated sample. (Figure 4B) Wnt5a-induced Rac1 activation was measured in untreated ROR-1 x TCL1 leukemia cells or ROR-1 x TCL1 leukemia cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 4C) CD154-induced proliferation of CFSE-labeled ROR-1×TCL1 leukemia cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative ROR-1×TCL1 leukemia cell sample is shown together with the cell division rate. (FIG. 4D) Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 4D]Figures 4A-4D. UC-961 inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 4A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a as indicated at the top of each lane and treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The numbers below each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized to the untreated sample. (Figure 4B) Wnt5a-induced Rac1 activation was measured in untreated ROR-1 x TCL1 leukemia cells or ROR-1 x TCL1 leukemia cells treated with UC-961 (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 4C) CD154-induced proliferation of CFSE-labeled ROR-1×TCL1 leukemia cells (n=6) treated with UC-961 or ibrutinib with or without Wnt5a. One representative ROR-1×TCL1 leukemia cell sample is shown together with the cell division rate. (FIG. 4D) Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 5A]5A-5C. Additive inhibitory effect of UC-961 and ibrutinib in ROR-1×TCL1 leukemia xenografted mice. (FIG. 5A) A representative spleen from a Rag2− / −γc− / − mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 5B) The combination of UC-961 and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2− / −γc− / − mice. Rag2− / −γc− / − mice were transplanted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg UC-961 on day 1 or daily administration of 5 mg / kg ibrutinib. Contour plots showing the fluorescence of splenic lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=5) receiving the treatments indicated at the top, as determined by light scattering characteristics after staining the cells with fluorescent dyes specific for B220 (ordinate) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 5C) Total number of ROR-1×TCL1 leukemic cells in the spleens of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, as determined by flow cytometric analysis and cell counting, that received a single injection of UC-961 at 1 mg / kg or daily injections of ibrutinib at 5 mg / kg. Each shape represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 5B]5A-5C. Additive inhibitory effect of UC-961 and ibrutinib in ROR-1×TCL1 leukemia xenografted mice. (FIG. 5A) A representative spleen from a Rag2− / −γc− / − mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 5B) The combination of UC-961 and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2− / −γc− / − mice. Rag2− / −γc− / − mice were transplanted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg UC-961 on day 1 or daily administration of 5 mg / kg ibrutinib. Contour plots showing the fluorescence of splenic lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=5) receiving the treatments indicated at the top, as determined by light scattering characteristics after staining the cells with fluorescent dyes specific for B220 (ordinate) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 5C) Total number of ROR-1×TCL1 leukemic cells in the spleens of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, as determined by flow cytometric analysis and cell counting, that received a single injection of UC-961 at 1 mg / kg or daily injections of ibrutinib at 5 mg / kg. Each shape represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 5C]5A-5C. Additive inhibitory effect of UC-961 and ibrutinib in ROR-1×TCL1 leukemia xenografted mice. (FIG. 5A) A representative spleen from a Rag2− / −γc− / − mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 5B) The combination of UC-961 and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2− / −γc− / − mice. Rag2− / −γc− / − mice were transplanted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg UC-961 on day 1 or daily administration of 5 mg / kg ibrutinib. Contour plots showing the fluorescence of splenic lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=5) receiving the treatments indicated at the top, as determined by light scattering characteristics after staining the cells with fluorescent dyes specific for B220 (ordinate) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 5C) Total number of ROR-1×TCL1 leukemic cells in the spleens of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, as determined by flow cytometric analysis and cell counting, that received a single injection of UC-961 at 1 mg / kg or daily injections of ibrutinib at 5 mg / kg. Each shape represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 6A]6A-6D. Ibrutinib inhibits BCR signaling but not Wnt5a / ROR-1 signaling. (Figure 6A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a or ibrutinib at concentrations of 0, 0.25, 0.5, or 1.0 μM, as indicated at the top of each lane. (Figure 6B) CLL cells were treated with increasing concentrations of ibrutinib for 1 hour and then assayed for BTK active site occupancy. (Figure 6C) Anti-μ induced calcium mobilization in CLL cells after treatment with or without different doses of ibrutinib. Relative mean fluorescence intensity in intracellular calcium is plotted as a function of time. The arrow labeled "IgM" indicates the time when anti-μ was added to the cells. (Figure 6D) Determination of cell viability by staining with DiOC6 and PI. Shown are dot maps of CLL cells from a representative patient, defining the relative fluorescence intensity of green (DiOC6) and red (PI) in leukemic cell intensity on the horizontal and vertical axes, respectively. The number of viable cells (DiOC6+PI-) was determined for CLL cells after treatment with different doses of ibrutinib. The percentage of viable cells is shown in each dot map. [Figure 6B]6A-6D. Ibrutinib inhibits BCR signaling but not Wnt5a / ROR-1 signaling. (Figure 6A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a or ibrutinib at concentrations of 0, 0.25, 0.5, or 1.0 μM, as indicated at the top of each lane. (Figure 6B) CLL cells were treated with increasing concentrations of ibrutinib for 1 hour and then assayed for BTK active site occupancy. (Figure 6C) Anti-μ induced calcium mobilization in CLL cells after treatment with or without different doses of ibrutinib. Relative mean fluorescence intensity in intracellular calcium is plotted as a function of time. The arrow labeled "IgM" indicates the time when anti-μ was added to the cells. (Figure 6D) Determination of cell viability by staining with DiOC6 and PI. Shown are dot maps of CLL cells from a representative patient, defining the relative fluorescence intensity of green (DiOC6) and red (PI) in leukemic cell intensity on the horizontal and vertical axes, respectively. The number of viable cells (DiOC6+PI-) was determined for CLL cells after treatment with different doses of ibrutinib. The percentage of viable cells is shown in each dot map. [Figure 6C]6A-6D. Ibrutinib inhibits BCR signaling but not Wnt5a / ROR-1 signaling. (Figure 6A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a or ibrutinib at concentrations of 0, 0.25, 0.5, or 1.0 μM, as indicated at the top of each lane. (Figure 6B) CLL cells were treated with increasing concentrations of ibrutinib for 1 hour and then assayed for BTK active site occupancy. (Figure 6C) Anti-μ induced calcium mobilization in CLL cells after treatment with or without different doses of ibrutinib. Relative mean fluorescence intensity in intracellular calcium is plotted as a function of time. The arrow labeled "IgM" indicates the time when anti-μ was added to the cells. (Figure 6D) Determination of cell viability by staining with DiOC6 and PI. Shown are dot maps of CLL cells from a representative patient, defining the relative fluorescence intensity of green (DiOC6) and red (PI) in leukemic cell intensity on the horizontal and vertical axes, respectively. The number of viable cells (DiOC6+PI-) was determined for CLL cells after treatment with different doses of ibrutinib. The percentage of viable cells is shown in each dot map. [Figure 6D]6A-6D. Ibrutinib inhibits BCR signaling but not Wnt5a / ROR-1 signaling. (Figure 6A) Active Rac1 was measured in CLL cells incubated with or without Wnt5a or ibrutinib at concentrations of 0, 0.25, 0.5, or 1.0 μM, as indicated at the top of each lane. (Figure 6B) CLL cells were treated with increasing concentrations of ibrutinib for 1 hour and then assayed for BTK active site occupancy. (Figure 6C) Anti-μ induced calcium mobilization in CLL cells after treatment with or without different doses of ibrutinib. Relative mean fluorescence intensity in intracellular calcium is plotted as a function of time. The arrow labeled "IgM" indicates the time when anti-μ was added to the cells. (Figure 6D) Determination of cell viability by staining with DiOC6 and PI. Shown are dot maps of CLL cells from a representative patient, defining the relative fluorescence intensity of green (DiOC6) and red (PI) in leukemic cell intensity on the horizontal and vertical axes, respectively. The number of viable cells (DiOC6+PI-) was determined for CLL cells after treatment with different doses of ibrutinib. The percentage of viable cells is shown in each dot map. [Figure 7A]7A-7E. Wnt5a induces Rac1 activation in CLL cells treated with ibrutinib. (FIG. 7A) CFSE assay for Wnt5a-induced CLL proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate shown at the bottom left of each panel. (FIG. 7B) CFSE assay for Wnt5a-induced ROR-1×TCL1 leukemia cell proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate indicated at the bottom left of each panel. (Figure 7C) Rac1 activation was measured in serum-starved TCL1 leukemia cells treated with Wnt5a for 30 min. Total cell lysates were run on parallel gels to probe for total Rac1. The numbers under each lane are the ratio of active GTPase band IOD to total GTPase normalized with respect to untreated samples. (Figure 7D) CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10 without or with exogenous Wnt5a. The results of the assay for one representative TCL1 leukemia sample are shown with the cell division rate indicated at the bottom left of each panel. (FIG. 7E) Mean division percentage of CLL cells from TCL1 leukemia cells (n=3) under the conditions indicated at the bottom. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. ns: not significant. [Figure 7B]7A-7E. Wnt5a induces Rac1 activation in CLL cells treated with ibrutinib. (FIG. 7A) CFSE assay for Wnt5a-induced CLL proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate shown at the bottom left of each panel. (FIG. 7B) CFSE assay for Wnt5a-induced ROR-1×TCL1 leukemia cell proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate indicated at the bottom left of each panel. (Figure 7C) Rac1 activation was measured in serum-starved TCL1 leukemia cells treated with Wnt5a for 30 min. Total cell lysates were run on parallel gels to probe for total Rac1. The numbers under each lane are the ratio of active GTPase band IOD to total GTPase normalized with respect to untreated samples. (Figure 7D) CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10 without or with exogenous Wnt5a. The results of the assay for one representative TCL1 leukemia sample are shown with the cell division rate indicated at the bottom left of each panel. (FIG. 7E) Mean division percentage of CLL cells from TCL1 leukemia cells (n=3) under the conditions indicated at the bottom. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. ns: not significant. [Figure 7C]7A-7E. Wnt5a induces Rac1 activation in CLL cells treated with ibrutinib. (FIG. 7A) CFSE assay for Wnt5a-induced CLL proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate shown at the bottom left of each panel. (FIG. 7B) CFSE assay for Wnt5a-induced ROR-1×TCL1 leukemia cell proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate indicated at the bottom left of each panel. (Figure 7C) Rac1 activation was measured in serum-starved TCL1 leukemia cells treated with Wnt5a for 30 min. Total cell lysates were run on parallel gels to probe for total Rac1. The numbers under each lane are the ratio of active GTPase band IOD to total GTPase normalized with respect to untreated samples. (Figure 7D) CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10 without or with exogenous Wnt5a. The results of the assay for one representative TCL1 leukemia sample are shown with the cell division rate indicated at the bottom left of each panel. (FIG. 7E) Mean division percentage of CLL cells from TCL1 leukemia cells (n=3) under the conditions indicated at the bottom. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. ns: not significant. [Figure 7D]7A-7E. Wnt5a induces Rac1 activation in CLL cells treated with ibrutinib. (FIG. 7A) CFSE assay for Wnt5a-induced CLL proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate shown at the bottom left of each panel. (FIG. 7B) CFSE assay for Wnt5a-induced ROR-1×TCL1 leukemia cell proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate indicated at the bottom left of each panel. (Figure 7C) Rac1 activation was measured in serum-starved TCL1 leukemia cells treated with Wnt5a for 30 min. Total cell lysates were run on parallel gels to probe for total Rac1. The numbers under each lane are the ratio of active GTPase band IOD to total GTPase normalized with respect to untreated samples. (Figure 7D) CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10 without or with exogenous Wnt5a. The results of the assay for one representative TCL1 leukemia sample are shown with the cell division rate indicated at the bottom left of each panel. (FIG. 7E) Mean division percentage of CLL cells from TCL1 leukemia cells (n=3) under the conditions indicated at the bottom. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. ns: not significant. [Figure 7E]7A-7E. Wnt5a induces Rac1 activation in CLL cells treated with ibrutinib. (FIG. 7A) CFSE assay for Wnt5a-induced CLL proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate shown at the bottom left of each panel. (FIG. 7B) CFSE assay for Wnt5a-induced ROR-1×TCL1 leukemia cell proliferation without CD154. Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with HeLa cells for 5 days in the presence of IL-4 / 10 without (left panel) or with (right panel) exogenous Wnt5a. The results of the assay for one representative CLL sample are shown with the cell division rate indicated at the bottom left of each panel. (Figure 7C) Rac1 activation was measured in serum-starved TCL1 leukemia cells treated with Wnt5a for 30 min. Total cell lysates were run on parallel gels to probe for total Rac1. The numbers under each lane are the ratio of the band IOD of activated GTPase to total GTPase, normalized with respect to untreated samples. (Figure 7D) CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10, without or with exogenous Wnt5a. The results of the assay for one representative TCL1 leukemia sample are shown with the cell division rate indicated at the bottom left of each panel. (FIG. 7E) Mean division percentage of CLL cells from TCL1 leukemia cells (n=3) under the conditions indicated at the bottom. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. ns: not significant. [Figure 8A]Figures 8A-8B. Dose-dependent inhibitory effect of UC-961 or ibrutinib in ROR-1 x TCL1 leukemia xenografted mice. (Figure 8A) Dose-dependent inhibitory effect of ibrutinib in ROR-1 x TCL1 leukemia xenografted mice. (Figure 8B) Dose-dependent inhibitory effect of UC-961 in ROR-1 x TCL1 leukemia xenografted mice. Each shape represents the number of leukemia cells found in an individual mouse. For each animal group (n=6), data are shown as mean±SEM. *P<0.05; ***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 8B] Figures 8A-8B. Dose-dependent inhibitory effect of UC-961 or ibrutinib in ROR-1 x TCL1 leukemia xenografted mice. (Figure 8A) Dose-dependent inhibitory effect of ibrutinib in ROR-1 x TCL1 leukemia xenografted mice. (Figure 8B) Dose-dependent inhibitory effect of UC-961 in ROR-1 x TCL1 leukemia xenografted mice. Each shape represents the number of leukemia cells found in an individual mouse. For each animal group (n=6), data are shown as mean±SEM. *P<0.05; ***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 9] Figure 9. ROR-1 was induced by BCR signaling inhibitors. [Figure 10] Figure 10. Additive effect of anti-ROR-1 antibody together with ibrutinib on CLL cell elimination in a niche-dependent animal model. [Figure 11] Figure 11. Additive effect of anti-ROR-1 antibodies in combination with ibrutinib on ROR-1xTCL1 murine leukemia. [Figure 12A]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 12B]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 12C]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 12D]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 12E]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 12F]Figures 12A-12F. Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated CLL cells. (Figure 12A) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium without or with exogenous Wnt5a (200 ng / ml) as indicated at the top of each lane. (Figure 12B) Active Rac1 was measured in freshly isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum-free medium with or without exogenous Wnt5a (200 ng / ml). The average Rac1 activation observed in four independent experiments is shown (n=4). (Figure 12C) CLL cells were collected from ibrutinib-treated patients (n=4). Active Rac1 was measured in CLL cells treated with or without Wnt5a (200 ng / ml) or cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot (FIG. 12D). Rac1 activation was measured in CLL cells collected from patients undergoing treatment with ibrutinib and treated with Wnt5a (200 ng / ml) and / or cirumtuzumab (10 μg / ml). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 12E) Active Rac1 was measured in CLL cells incubated with or without Wnt5a and treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) as indicated above each lane. (FIG. 12F) Wnt5a-induced Rac1 activation in untreated CLL cells or cirumtuzumab and / or ibrutinib-treated CLL cells. The average Rac1 activation observed in five independent experiments is shown (n=5). The numbers under each lane are the ratio of active GTPase band IOD to total GTPase, normalized to untreated samples. For each group, data are shown as mean±SEM. **P<0.01; ***P<0.001; ****P<0.0001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 13A]Figures 13A-13D. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 13A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) with or without Wnt5a. One representative CLL sample is shown with cell division rate. (Figure 13B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of six different patients for each culture condition shown at the bottom. (Figure 13C) CLL cells were co-cultured on HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (FIG. 13D) The average fraction of cells in S / G2 / M phase for all four patients tested is shown. Data are presented as mean±SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 13B]Figures 13A-13D. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 13A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) with or without Wnt5a. One representative CLL sample is shown with cell division rate. (Figure 13B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of six different patients for each culture condition shown at the bottom. (Figure 13C) CLL cells were co-cultured on HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (FIG. 13D) The average fraction of cells in S / G2 / M phase for all four patients tested is shown. Data are presented as mean±SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 13C]Figures 13A-13D. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 13A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) with or without Wnt5a. One representative CLL sample is shown with cell division rate. (Figure 13B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of six different patients for each culture condition shown at the bottom. (Figure 13C) CLL cells were co-cultured on HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (FIG. 13D) The average fraction of cells in S / G2 / M phase for all four patients tested is shown. Data are presented as mean±SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 13D]Figures 13A-13D. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL cells. (Figure 13A) CD154-induced proliferation of CFSE-labeled CLL cells (n=6) treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) with or without Wnt5a. One representative CLL sample is shown with cell division rate. (Figure 13B) Bars indicate the average percentage of CLL cells with reduced CFSE fluorescence from each of six different patients for each culture condition shown at the bottom. (Figure 13C) CLL cells were co-cultured on HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with silmutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (FIG. 13D) The average fraction of cells in S / G2 / M phase for all four patients tested is shown. Data are presented as mean±SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 14A] 14A-14B. Effect of treatment with cirumtuzumab and / or ibrutinib in xenografts derived from CLL patients. (FIG. 14A) CLL cells were injected into the peritoneal cavity of Rag2- / -γc- / - mice one day before treatment. Peritoneal lavage fluid was collected 7 days after cell injection, and residual CLL was determined by cell counting and flow cytometry analysis after staining with mAbs specific for CD5, CD19, and CD45. The percentages shown in the upper right corner of each contour plot indicate the proportion of CLL cells among cells collected from mice after treatment. (FIG. 14B) Each bar on the graph represents the percentage of CLL cells among cells collected from mice after treatment, normalized to the percentage of CLL cells among cells collected from untreated mice (to 100%). Data shown are mean ± SEM from 3 different patients with 5 mice in each group. ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 14B]14A-14B. Effect of treatment with cirumtuzumab and / or ibrutinib on xenografts derived from CLL patients. (FIG. 14A) CLL cells were injected into the peritoneal cavity of Rag2- / -γc- / - mice one day before treatment. Peritoneal lavage fluid was collected 7 days after cell injection and residual CLL was determined by cell counting and flow cytometry analysis after staining with mAbs specific for CD5, CD19 and CD45. The percentages shown in the upper right corner of each contour plot indicate the proportion of CLL cells among cells collected from mice after treatment. (FIG. 14B) Each bar on the graph represents the percentage of CLL cells among cells collected from treated mice normalized to the percentage of CLL cells among cells collected from untreated mice (to 100%). Data shown are mean ± SEM from 3 different patients with 5 mice in each group. ***P<0.001; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 15A]Figures 15A-15C. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 15A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a (200 ng / ml) and treated with silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM) as indicated at the top of each lane. The numbers below each lane are the ratio of band density of active GTPase to total GTPase, normalized to untreated samples. (Figure 15B) Activation of Rac1 in ROR-1 x TCL1 leukemia cells treated with Wnt5a with or without silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 15C) CD154-induced proliferation in CFSE-labeled ROR-1×TCL1 leukemia cells (n=5) treated or untreated with Wnt5a (200 ng / ml) and / or cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM). Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. *P<0.05; **P<0.01; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 15B]Figures 15A-15C. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 15A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a (200 ng / ml) and treated with silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM) as indicated at the top of each lane. The numbers below each lane are the ratio of band density of active GTPase to total GTPase, normalized to untreated samples. (Figure 15B) Activation of Rac1 in ROR-1 x TCL1 leukemia cells treated with Wnt5a with or without silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 15C) CD154-induced proliferation in CFSE-labeled ROR-1×TCL1 leukemia cells (n=5) treated or untreated with Wnt5a (200 ng / ml) and / or cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM). Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. *P<0.05; **P<0.01; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 15C]Figures 15A-15C. Sirmutuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR-1 x TCL1 leukemia cells. (Figure 15A) Activated Rac1 was measured in ROR-1 x TCL1 leukemia cells incubated with or without Wnt5a (200 ng / ml) and treated with silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM) as indicated at the top of each lane. The numbers below each lane are the ratio of band density of active GTPase to total GTPase, normalized to untreated samples. (Figure 15B) Activation of Rac1 in ROR-1 x TCL1 leukemia cells treated with Wnt5a with or without silmutuzumab (10 μg / ml) and / or ibrutinib (0.5 μM). The average Rac1 activation observed in five independent experiments is shown (n=5). (FIG. 15C) CD154-induced proliferation in CFSE-labeled ROR-1×TCL1 leukemia cells (n=5) treated or untreated with Wnt5a (200 ng / ml) and / or cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM). Bars indicate the average percentage of ROR-1×TCL1 leukemia cells with reduced CFSE fluorescence from each of five different mice for each culture condition shown at the bottom. Data are shown as mean±SEM. *P<0.05; **P<0.01; ****P<0.0001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 16A]16A-16C. Additive inhibitory effect of treatment with cirumtuzumab and ibrutinib in immune-deficient mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 16A) A representative spleen from a Rag2- / -γc- / - mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 16B) The combination of cirumtuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2- / -γc- / - mice. Rag2- / -γc- / - mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg cirumtuzumab on day 1 or daily ibrutinib at 5 mg / kg by oral ingestion. Contour plots showing fluorescence after staining of lymphocytes 25 days after adoptive cell transfer from representative mice (n=5) treated as indicated at the top, using fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 16C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving a single injection of 1 mg / kg cirumutuzumab or daily injections of 5 mg / kg ibrutinib. Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.*P<0.05, **P<0.01, ***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 16B]16A-16C. Additive inhibitory effect of treatment with cirumtuzumab and ibrutinib in immune-deficient mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 16A) A representative spleen from a Rag2- / -γc- / - mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 16B) The combination of cirumtuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2- / -γc- / - mice. Rag2- / -γc- / - mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg cirumtuzumab on day 1 or daily ibrutinib at 5 mg / kg by oral ingestion. Contour plots showing fluorescence of lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=5) treated as indicated at the top, after staining the cells with fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 16C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving a single injection of 1 mg / kg cirumutuzumab or daily injections of 5 mg / kg ibrutinib. Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.*P<0.05, **P<0.01, ***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 16C]16A-16C. Additive inhibitory effect of treatment with cirumtuzumab and ibrutinib in immune-deficient mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 16A) A representative spleen from a Rag2- / -γc- / - mouse collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells is shown. (FIG. 16B) The combination of cirumtuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in Rag2- / -γc- / - mice. Rag2- / -γc- / - mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered a single intravenous injection of 1 mg / kg cirumtuzumab on day 1 or daily ibrutinib at 5 mg / kg by oral ingestion. Contour plots showing fluorescence of lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=5) treated as indicated at the top, after staining the cells with fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 16C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient Rag2− / −γc− / − mice 25 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving a single injection of 1 mg / kg cirumutuzumab or daily injections of 5 mg / kg ibrutinib. Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=5), data are presented as the mean±SEM.*P<0.05, **P<0.01, ***P<0.001 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 17A]17A-17C. Additive inhibitory effect of treatment with cirumutuzumab and ibrutinib in immunocompetent mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 17A) A representative spleen from a ROR-1-Tg mouse is shown, collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells. (FIG. 17B) The combination of cirumutuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in ROR-1-Tg mice. ROR-1-Tg mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered 10 mg / kg cirumutuzumab intravenously once a week or 5 mg / kg ibrutinib by oral ingestion daily. Contour plots of lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=6) treated as indicated at the top, after staining the cells with fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 17C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient ROR-1-Tg mice 28 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving weekly injections of 10 mg / kg cirumutuzumab and / or daily injections of ibrutinib (at 5 mg / kg). Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=6), data are presented as the mean±SEM.*P<0.05;**P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 17B]17A-17C. Additive inhibitory effect of treatment with cirumutuzumab and ibrutinib in immunocompetent mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 17A) A representative spleen from a ROR-1-Tg mouse is shown, collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells. (FIG. 17B) The combination of cirumutuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in ROR-1-Tg mice. ROR-1-Tg mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered 10 mg / kg cirumutuzumab intravenously once a week or 5 mg / kg ibrutinib by oral ingestion daily. Contour plots of lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=6) treated as indicated at the top, after staining the cells with fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 17C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient ROR-1-Tg mice 28 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving weekly injections of 10 mg / kg cirumutuzumab and / or daily injections of ibrutinib (at 5 mg / kg). Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=6), data are presented as the mean±SEM.*P<0.05;**P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 17C]17A-17C. Additive inhibitory effect of treatment with cirumutuzumab and ibrutinib in immunocompetent mice engrafted with histocompatible ROR-1+ leukemia. (FIG. 17A) A representative spleen from a ROR-1-Tg mouse is shown, collected 25 days after receiving an intravenous injection of 2×104 ROR-1×TCL1 leukemia cells. (FIG. 17B) The combination of cirumutuzumab and ibrutinib inhibits the engraftment of ROR-1×TCL1 leukemia cells in ROR-1-Tg mice. ROR-1-Tg mice were engrafted with 2×104 ROR-1×TCL1 leukemia cells and then administered 10 mg / kg cirumutuzumab intravenously once a week or 5 mg / kg ibrutinib by oral ingestion daily. Contour plots of lymphocytes collected 25 days after adoptive cell transfer from representative mice (n=6) treated as indicated at the top, after staining the cells with fluorochrome-conjugated mAbs specific for B220 (axis) and human ROR-1 (ordinate). The percentages at the top right of each contour plot indicate the proportion of blood mononuclear cells with the CD5+B220lowROR-1+ phenotype of leukemic cells. (FIG. 17C) Total number of ROR-1×TCL1 leukemic cells in the spleen of recipient ROR-1-Tg mice 28 days after adoptive cell transfer of 2×104 ROR-1×TCL1 leukemic cells, receiving weekly injections of 10 mg / kg cirumutuzumab and / or daily injections of ibrutinib (at 5 mg / kg). Each symbol represents the number of leukemic cells found in an individual mouse. For each group of animals (n=6), data are presented as the mean±SEM.*P<0.05;**P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 18A]18A-18B. CFSE assay for Wnt5a-induced CLL proliferation without CD154. (FIG. 18A) Gating strategy for sorting CLL cells. Cells were first gated for size and singleness, and then live cells were identified for further analysis by PI exclusion. Fluorescence was examined for live CD5 and CD19 CLL cells after staining with CFSE. The division rate of CLL cells was calculated by calculating the percentage of cells with low CFSE fluorescence. (FIG. 18B) Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (upper panel) or with (lower panel) exogenous Wnt5a. Results for one representative CLL sample are shown with the division rate of cells shown below the left corner of each histogram. [Figure 18B] 18A-18B. CFSE assay for Wnt5a-induced CLL proliferation without CD154. (FIG. 18A) Gating strategy for sorting CLL cells. Cells were first gated for size and singleness, then live cells were identified for further analysis by PI exclusion. Fluorescence was examined for live CD5 and CD19 CLL cells after staining with CFSE. The division rate of CLL cells was calculated by calculating the percentage of cells with low CFSE fluorescence. (FIG. 18B) Fluorescence of CFSE-labeled CLL cells (n=6) co-cultured with wild-type HeLa cells for 5 days in the presence of IL-4 / 10 without (upper panel) or with (lower panel) exogenous Wnt5a. Results for one representative CLL sample are shown with the division rate of cells shown below the left corner of each histogram. [Figure 19A]Figures 19A-19B. Cell cycle analysis of CLL cells treated with cirumtuzumab or ibrutinib with or without exogenous Wnt5a. (Figure 19A) Leukemic cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative leukemic sample is shown. (Figure 19B) The average percentage of leukemic cells in S / G2 / M phase for all three samples is shown. Data are presented as mean ± SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 19B] Figures 19A-19B. Cell cycle analysis of CLL cells treated with cirumtuzumab or ibrutinib with or without exogenous Wnt5a. (Figure 19A) Leukemic cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumtuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative leukemic sample is shown. (Figure 19B) The average percentage of leukemic cells in S / G2 / M phase for all three samples is shown. Data are presented as mean ± SEM, *P<0.05; **P<0.01 as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 20A] Figures 20A-20B. Dose-dependent inhibitory effect of cirumutuzumab or ibrutinib in ROR-1 x TCL1 leukemia-engrafted mice. (Figure 20A) Dose-dependent inhibitory effect of ibrutinib in ROR-1 x TCL1 leukemia-engrafted mice. (Figure 20B) Dose-dependent inhibitory effect of cirumutuzumab in ROR-1 x TCL1 leukemia-engrafted mice. Each symbol represents the number of leukemia cells found in an individual mouse. For each animal group (n=6), data are shown as mean±SEM. *P<0.05; ***P<0.001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 20B]Figures 20A-20B. Dose-dependent inhibitory effect of cirumutuzumab or ibrutinib in ROR-1 x TCL1 leukemia-engrafted mice. (Figure 20A) Dose-dependent inhibitory effect of ibrutinib in ROR-1 x TCL1 leukemia-engrafted mice. (Figure 20B) Dose-dependent inhibitory effect of cirumutuzumab in ROR-1 x TCL1 leukemia-engrafted mice. Each symbol represents the number of leukemia cells found in an individual mouse. For each animal group (n=6), data are shown as mean±SEM. *P<0.05; ***P<0.001, as calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 21] Figure 21. CFSE assay for TCL1 leukemia cell proliferation induced by Wnt5a and / or CD154. Fluorescence of CFSE-labeled TCL1 leukemia cells (n=3) co-cultured with wild-type HeLa cells or HeLaCD154 cells for 5 days in the presence of IL-4 / 10 without or with exogenous Wnt5a. For each group, data are shown as mean±SEM. p-values were calculated using one-way ANOVA with Tukey's multiple comparison test. [Figure 22A] Figures 22A-22C. Antigen expression in primary MCL and Wnt5a levels in MCL patient plasma. (Figure 22A) Gating on MCL cells expressing CD5 and CD19 (top left). Shaded histograms show fluorescence of gated MCL cells stained with fluorochrome-conjugated mAbs specific for other surface antigens. In contrast to CLL cells, MCL cells could not be stained with mAbs specific for CD200 (top right) or CD23 (bottom left). Similar to CLL, MCL expresses high levels of ROR-1 (bottom right). Open histograms show fluorescence of cells stained with isotopic control antibody. (Figure 22B) ΔMFI of ROR-1 in MCL vs. CLL. ns = not significant. (Figure 22C) Plasma Wnt5a in MCL patients versus age-matched control subjects (n = 4 per group; P < 0.05, Student's t-test). [Figure 22B]Figures 22A-22C. Antigen expression in primary MCL and Wnt5a levels in MCL patient plasma. (Figure 22A) Gating on MCL cells expressing CD5 and CD19 (top left). Shaded histograms show fluorescence of gated MCL cells stained with fluorochrome-conjugated mAbs specific for other surface antigens. In contrast to CLL cells, MCL cells could not be stained with mAbs specific for CD200 (top right) or CD23 (bottom left). Similar to CLL, MCL expresses high levels of ROR-1 (bottom right). Open histograms show fluorescence of cells stained with isotopic control antibody. (Figure 22B) ΔMFI of ROR-1 in MCL vs. CLL. ns = not significant. (Figure 22C) Plasma Wnt5a in MCL patients versus age-matched control subjects (n = 4 per group; P < 0.05, Student's t-test). [Figure 22C] Figures 22A-22C. Antigen expression in primary MCL and Wnt5a levels in MCL patient plasma. (Figure 22A) Gating on MCL cells expressing CD5 and CD19 (top left). Shaded histograms show fluorescence of gated MCL cells stained with fluorochrome-conjugated mAbs specific for other surface antigens. In contrast to CLL cells, MCL cells could not be stained with mAbs specific for CD200 (top right) or CD23 (bottom left). Similar to CLL, MCL expresses high levels of ROR-1 (bottom right). Open histograms show fluorescence of cells stained with isotopic control antibody. (Figure 22B) ΔMFI of ROR-1 in MCL vs. CLL. ns = not significant. (Figure 22C) Plasma Wnt5a in MCL patients versus age-matched control subjects (n = 4 per group; P < 0.05, Student's t-test). [Figure 23A]Figures 23A-23D. Analysis of Rac1 activation and cell cycle in MCL cells. (Figure 23A) Activated Rac1 was measured in MCL cells treated with or without Wnt5a (200 ng / ml), with or without ibrutinib (0.5 μM), with or without cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot. The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. (Figure 23B) Activation of Rac1 induced by Wnt5a in untreated CLL cells or CLL cells treated with cirumtuzumab and / or ibrutinib. The average Rac1 activation observed in five independent experiments is shown (n=3). The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. For each group, data are presented as mean ± SEM. ****P<0.0001 when calculated using one-way ANOVA with Tukey's multiple comparison test. (Figure 23C) MCL cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (Figure 23D) The average fraction of cells in S / G2 phase for all MCL patients tested is shown (n=3). Data are presented as mean ± SEM, *P<0.05; **P<0.01 when calculated using one-way ANOVA with Tukey's multiple comparison test. ns=not significant. [Figure 23B]Figures 23A-23D. Analysis of Rac1 activation and cell cycle in MCL cells. (Figure 23A) Activated Rac1 was measured in MCL cells treated with or without Wnt5a (200 ng / ml), with or without ibrutinib (0.5 μM), with or without cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot. The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. (Figure 23B) Activation of Rac1 induced by Wnt5a in untreated CLL cells or CLL cells treated with cirumtuzumab and / or ibrutinib. The average Rac1 activation observed in five independent experiments is shown (n=3). The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. For each group, data are presented as mean ± SEM. ****P<0.0001 when calculated using one-way ANOVA with Tukey's multiple comparison test. (Figure 23C) MCL cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (Figure 23D) The average fraction of cells in S / G2 phase for all MCL patients tested is shown (n=3). Data are presented as mean ± SEM, *P<0.05; **P<0.01 when calculated using one-way ANOVA with Tukey's multiple comparison test. ns=not significant. [Figure 23C]Figures 23A-23D. Analysis of Rac1 activation and cell cycle in MCL cells. (Figure 23A) Activated Rac1 was measured in MCL cells treated with or without Wnt5a (200 ng / ml), with or without ibrutinib (0.5 μM), with or without cirumtuzumab (10 μg / ml) as indicated above each lane of the immunoblot. The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. (Figure 23B) Activation of Rac1 induced by Wnt5a in untreated CLL cells or CLL cells treated with cirumtuzumab and / or ibrutinib. The average Rac1 activation observed in five independent experiments is shown (n=3). The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. For each group, data are presented as mean ± SEM. ****P<0.0001 when calculated using one-way ANOVA with Tukey's multiple comparison test. (Figure 23C) MCL cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (Figure 23D) The average fraction of cells in S / G2 phase for all MCL patients tested is shown (n=3). Data are presented as mean ± SEM, *P<0.05; **P<0.01 when calculated using one-way ANOVA with Tukey's multiple comparison test. ns=not significant. [Figure 23D]Figures 23A-23D. Analysis of Rac1 activation and cell cycle in MCL cells. (Figure 23A) Activated Rac1 was measured in MCL cells treated with or without Wnt5a (200 ng / ml), with or without ibrutinib (0.5 μM), with or without cirumtuzumab (10 μg / ml), as indicated above each lane of the immunoblot. The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. (Figure 23B) Wnt5a-induced activation of Rac1 in CLL cells untreated or treated with cirumtuzumab and / or ibrutinib. The average Rac1 activation observed in five independent experiments is shown (n=3). The numbers below each lane are the ratio of the band IOD of the activated to the total GTPase, normalized to the untreated sample. For each group, data are presented as mean ± SEM. ****P<0.0001 when calculated using one-way ANOVA with Tukey's multiple comparison test. (Figure 23C) MCL cells were co-cultured with HeLaCD154 in the presence of IL-4 / 10 or Wnt5a, then treated with cirumutuzumab (10 μg / ml) or ibrutinib (0.5 μM) for 4 days, and cell cycle analysis was performed after PI staining. One representative CLL sample is shown. (Figure 23D) The average fraction of cells in S / G2 phase for all MCL patients tested is shown (n=3). Data are presented as mean ± SEM, *P<0.05; **P<0.01 when calculated using one-way ANOVA with Tukey's multiple comparison test. ns=not significant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] definition While various embodiments and aspects of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments and aspects are provided by way of example only. Numerous variations, changes, and substitutions are possible for those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in the practice of the invention.
[0014] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, manuals, and papers, are expressly incorporated herein by reference in their entirety for all purposes.
[0015] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulas set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
[0016] Where substituents are specified by a conventional chemical formula written from left to right, it equally encompasses the chemically identical substituents which result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0017] The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, straight-chain (i.e., unbranched) or branched, non-cyclic carbon chains (or carbons), or combinations thereof, which may be fully saturated, mono- or polysaturated, and include di- and polyvalent groups containing the specified number of carbon atoms (i.e., C1-C2). 10means 1 to 10 carbons). Examples of saturated hydrocarbon groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, and homologs and isomers thereof, such as n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Unsaturated alkyl groups are those with one or more double bonds or those with triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-O-). The alkyl moiety may be an alkenyl moiety. The alkyl moiety may be an alkynyl moiety. The alkyl moiety may be fully saturated. The alkenyl may contain, in addition to one or more double bonds, one or more double bonds and / or one or more triple bonds. The alkynyl may contain, in addition to one or more triple bonds, one or more triple bonds and / or one or more double bonds.
[0018] The term "alkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent group derived from an alkyl, as exemplified, but not limited to, by -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group contains from 1 to 24 carbon atoms, with groups containing 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having 8 or fewer carbon atoms. The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent group derived from an alkene.
[0019] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable linear or branched, acyclic group containing at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), where the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized, or combinations thereof. The heteroatom (e.g., O, N, P, Si, and S) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, -O-CH-2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. The heteroalkyl moiety may contain one heteroatom (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain two optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain three optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain four optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain five optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain eight optionally different heteroatoms (e.g., O, N, S, Si, or P). The term "heteroalkenyl", by itself or in combination with another term, means a heteroalkyl containing at least one double bond, unless otherwise stated. The heteroalkenyl may optionally contain, in addition to one or more double bonds, more than one double bond and / or one or more triple bonds.The term "heteroalkynyl," by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl containing at least one triple bond. Heteroalkynyl can optionally contain, in addition to one or more triple bonds, more than one triple bond and / or one or more double bonds.
[0020] Similarly, the term "heteroalkylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent group derived from heteroalkyl, as exemplified, but not limited to, by -CH-CH-S-CH-CH- and -CH-S-CH-CH-NH-CH-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Additionally, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)R'- represents both -C(O)R'- and -R'C(O)-. As noted above, heteroalkyl groups, as used herein, include groups that are attached to the remainder of the molecule by a heteroatom, such as -C(O)R', -C(O)NR', -NR'R'', -OR', -SR' and / or -SOR'. When "heteroalkyl" is referenced followed by a list of specific heteroalkyl groups, such as -NR'R'', it will be understood that the terms heteroalkyl and -NR'R'' are not overlapping or mutually exclusive. Rather, the specific heteroalkyl groups are listed for added clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups, such as -NR'R''.
[0021] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, mean, unless otherwise specified, non-aromatic versions of "alkyl" and "heteroalkyl", respectively, where one or more of the ring carbons are not necessarily bonded to hydrogen due to all carbon valences involved in bonding with non-hydrogen atoms. Furthermore, in the case of heterocycloalkyl, a heteroatom may occupy the position at which the heterocycle is bonded to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, 3-hydroxy-cyclobut-3-enyl-1,2-dione, 1H-1,2,4-triazolyl-5(4H)-one, 4H-1,2,4-triazolyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. "Cycloalkylene" and "heterocycloalkylene," alone or as part of another substituent, refer to a divalent group derived from a cycloalkyl and a heterocycloalkyl, respectively. A heterocycloalkyl moiety may contain one ring heteroatom (e.g., O, N, S, Si, or P). A heterocycloalkyl moiety may contain two optionally different ring heteroatoms (e.g., O, N, S, Si, or P). A heterocycloalkyl moiety may contain three optionally different ring heteroatoms (e.g., O, N, S, Si, or P). A heterocycloalkyl moiety may contain four, optionally different, ring heteroatoms (e.g., O, N, S, Si, or P). A heterocycloalkyl moiety may contain five, optionally different, ring heteroatoms (e.g., O, N, S, Si, or P). A heterocycloalkyl moiety may contain up to eight, optionally different, ring heteroatoms (e.g., O, N, S, Si, or P).
[0022] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0023] The term "acyl," unless otherwise specified, means -C(O)R, where R is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0024] The term "aryl", unless otherwise specified, means a polyunsaturated aromatic hydrocarbon substituent, which may be a single ring, or multiple rings (preferably 1-3 rings) fused together (i.e., fused-ring aryl) or covalently linked. Fused-ring aryl refers to multiple fused rings, at least one of which is an aryl ring. The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom, such as N, O, or S, where the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Thus, the term "heteroaryl" includes fused-ring heteroaryl groups (i.e., multiple fused rings, where at least one of the fused rings is a heteroaromatic ring). 5,6-fused-ring heteroarylene refers to two fused rings, where one ring is 5-membered and the other ring is 6-membered, and where at least one ring is a heteroaryl ring. Similarly, 6,6-fused ring heteroarylene refers to two fused rings, one of which is 6-membered and the other is 6-membered, with at least one ring being a heteroaryl ring. Also, 6,5-fused ring heteroarylene refers to two fused rings, one of which is 6-membered and the other is 5-membered, with at least one ring being a heteroaryl ring. The heteroaryl group may be bonded to the rest of the molecule via a carbon atom or a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, and 5-isoxazolyl. , 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolyl.Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. "Arylene" and "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. Non-limiting examples of aryl and heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphthalyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzisoxazolyl, imidazopyridinyl, benzofuranyl, benzothienyl, benzothiophenyl, phenyl, naphthyl, biphenyl, Examples of heteroaryl include pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimidyl, benzothiazolyl, purinyl, benzimidazolyl, isoquinolyl, thiadiazolyl, oxadiazolyl, pyrrolyl, diazolyl, triazolyl, tetrazolyl, benzothiadiazolyl, isothiazolyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, benzotriazolyl, benzoxazolyl, and quinolyl. The above examples may be substituted or unsubstituted, and the divalent radicals of each of the above heteroaryl examples are non-limiting examples of heteroarylene. The heteroaryl moiety may contain one ring heteroatom (e.g., O, N, or S). The heteroaryl moiety may contain two optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain three optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain four optionally different ring heteroatoms (e.g., O, N, or S). The heteroaryl moiety may contain five optionally different ring heteroatoms (e.g., O, N, or S). The aryl moiety may have a single ring. The aryl moiety may have two optionally different rings. The aryl moiety may have three optionally different rings. The aryl moiety may have four optionally different rings. The heteroaryl moiety may have one ring.The heteroaryl moiety may have two, optionally different rings. The heteroaryl moiety may have three, optionally different rings. The heteroaryl moiety may have four, optionally different rings. The heteroaryl moiety may have five, optionally different rings.
[0025] A fused ring heterocycloalkylaryl is an aryl fused to a heterocycloalkyl. A fused ring heterocycloalkylheteroaryl is a heteroaryl fused to a heterocycloalkyl. A fused ring heterocycloalkylcycloalkyl is a heterocycloalkyl fused to a cycloalkyl. A fused ring heterocycloalkylheterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl. Each fused ring heterocycloalkylaryl, fused ring heterocycloalkylheteroaryl, fused ring heterocycloalkylcycloalkyl, or fused ring heterocycloalkylheterocycloalkyl can be independently unsubstituted or substituted with one or more substituents described herein.
[0026] The term "oxo," as used herein, means an oxygen attached to a carbon atom with a double bond.
[0027] The term "alkylsulfonyl," as used herein, refers to a moiety having the formula -S(O2)-R', where R' is a substituted or unsubstituted alkyl group as defined above. R' may contain a specified number of carbons (e.g., "C1-C4 alkylsulfonyl").
[0028] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl" and "heteroaryl") includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
[0029] Substituents for the alkyl and heteroalkyl groups (including groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) include, but are not limited to, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -COR', -CONR'R'', -OC(O)NR'R', -O ... m' may be one or more of a variety of groups selected from: -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)2R', -NR-C(NR'R''R'')=NR'''', -NR-C(NR'R'')=NR''', -S(O)R', -S(O)2R', -S(O)2NR'R'', -NRSO2R', -NR'NR''R''', -ONR'R'', -NR'C=(O)NR''NR''R'''', -CN, -NO2, where m' is the total number of carbon atoms in such groups. R, R', R'', R''', and R'''' each preferably independently represent hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When the compounds of the invention contain more than one R group, each R group is independently selected, as are, for example, each R', R'', R''', and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R'' includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand the term "alkyl" to be meant to include groups that contain carbon atoms bonded to groups other than hydrogen groups, such as haloalkyl (e.g., -CF and -CHCF) and acyl (e.g., -C(O)CH, -C(O)CF, -C(O)CHOCH, etc.).
[0030] Similar to the substituents described for the alkyl group, the substituents for the aryl and heteroaryl groups can vary and include, for example, -OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO2R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)2R', -NR-C(NR'R''R'')=NR'''', -NR-C(NR'R'')=NR''', -S(O)R', -S(O)2R', and R is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, each R group is independently selected, as are, for example, each R, R, R, and R groups when more than one of these groups is present.
[0031] Two or more substituents may be connected to optionally form an aryl group, a heteroaryl group, a cycloalkyl group, or a heterocycloalkyl group. Such so-called ring-forming substituents are typically, but not necessarily, found attached to a ring base structure. In some embodiments, the ring-forming substituents are attached to adjacent atoms of the base structure. For example, two ring-forming substituents attached to adjacent atoms of a ring base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single atom of the base structure. For example, two ring-forming substituents attached to a single atom of a ring base structure create a spiro ring structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent atoms of the base structure.
[0032] Two substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be represented by the formula -TC(O)-(CRR') q -U-, where T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Two substituents on adjacent atoms of the aryl or heteroaryl ring can optionally be represented by the formula -A-(CH2) r A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer from 1 to 4. One of the single bonds of the new ring thus formed may optionally be replaced with a double bond. Or, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a group of the formula -(CRR') s -X'-(C''R''R'') d-, where s and d are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituents R, R', R" and R'" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0033] As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P) and silicon (Si).
[0034] "Substituent," as used herein, means a group selected from the following moieties: (A) oxo, halogen, -CF3, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SON2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from the following: (i) oxo, halogen, -CF3, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SON2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from the following: (a) oxo, halogen, -CF3, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SON2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from the following: oxo, halogen, -CF3, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -SO4H, -SON2NH2, -NHNH2, -ONH2, -NHC=(O)NHNH2, -NHC=(O)NH2, -NHSO2H, -NHC=(O)H, -NHC(O)-OH, -NHOH, -OCF3, -OCHF2, unsubstituted alkyl, unsubstituted heteroaryl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl.
[0035] A "size-limited substituent" or "size-limited substituent group" as used herein means a group selected from all of the substituents described above for "substituent", where each substituted or unsubstituted alkyl is a substituted or unsubstituted C-C 20each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20-membered heteroalkyl; each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl; each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 8-membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl.
[0036] A "lower substituent" or "lower substituent group", as used herein, means a group selected from all of the substituents described above for "substituent", where each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3-7 membered heterocycloalkyl, and each substituted or unsubstituted aryl is a substituted or unsubstituted C6 ... 10 Aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 9-membered heteroaryl.
[0037] In some embodiments, each of the substituents described in the compounds herein is substituted with at least one substituent. More specifically, in some embodiments, the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene and / or substituted heteroarylene described in the compounds herein are each substituted with at least one substituent. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent. In other embodiments, at least one or all of these groups are substituted with at least one lower-rank substituent.
[0038] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl is a substituted or unsubstituted C-C 20 each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20-membered heteroalkyl; each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl; each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 8-membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C 20 each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2- to 20-membered heteroalkylene; each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene; each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3- to 8-membered heterocycloalkylene; each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C 10arylene, and / or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5- to 10-membered heteroarylene.
[0039] In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3-7 membered heterocycloalkyl, and each substituted or unsubstituted aryl is a substituted or unsubstituted C6 ... 10 In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2-8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3-7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C8 alkylene, each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5-9 membered heteroaryl, each substituted or unsubstituted ... 10 arylene, and / or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5- to 9-membered heteroarylene. In some embodiments, the compound is a species described in the Examples section, figures, or tables below.
[0040] The term "pharmaceutically acceptable salts" is intended to include salts of active compounds prepared using relatively non-toxic acids or bases, depending on the specific substituents found on the compounds described herein. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharma- ceutically acceptable acid addition salts include those derived from organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphate, dihydrogenphosphate, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, and those derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, or methanesulfonic acid. Salts of amino acids such as arginate, and salts of organic acids such as glucuronic acid or galacturonic acid are also included (see, for example, Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functional groups, and the compounds can be converted into base or acid addition salts. Other pharma- ceutically acceptable carriers known to those skilled in the art are suitable for the present invention. Salts tend to be more soluble in aqueous or other protic solvents than the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5-5.5, which is combined with a buffer prior to use.
[0041] Thus, the compounds of the present invention may exist as salts, for example, as salts with pharma- ceutically acceptable acids. The present invention includes such salts. Examples of such salts include hydrochloride, hydrobromide, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate (e.g., (+)-tartrate, (-)-tartrate, or mixtures thereof, including racemic mixtures), succinate, benzoate, and salts with amino acids, such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
[0042] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0043] Provided herein are agents (e.g., compounds, drugs, therapeutic agents) that may be in prodrug form. Prodrugs of the compounds described herein are compounds that readily undergo chemical changes under selected physiological conditions to provide the final agent (e.g., compound, drug, therapeutic agent). Additionally, prodrugs can be converted to agents (e.g., compounds, drugs, therapeutic agents) by chemical or biochemical methods in an ex vivo environment. Prodrugs described herein include compounds that readily undergo chemical changes under selected physiological conditions to provide agents (e.g., compounds, drugs, therapeutic agents) to a biological system (e.g., the biological system of a subject).
[0044] Certain compounds of the present invention may exist in unsolvated and solvated forms (including hydrated forms). In general, solvated forms are equivalent to unsolvated forms and are included within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the use envisioned for the present invention and are intended to be within the scope of the present invention.
[0045] As used herein, the term "salt" refers to an acid or base salt of a compound used in the method of the present invention. Specific examples of acceptable salts are salts of mineral acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, etc.), salts of organic acids (such as acetic acid, propionic acid, glutamic acid, citric acid, etc.), and salts of quaternary ammonium (such as methyl iodide, ethyl iodide, etc.).
[0046] Certain compounds of the present invention have asymmetric carbon atoms (optical or chiral centers) or double bonds. Stereoisomeric forms, which may be defined in terms of absolute stereochemistry as enantiomers, racemates, diastereomers, tautomers, geometric isomers, (R)- or (S)- or (D)- or (L)- of amino acids, are encompassed within the scope of the present invention. Compounds of the present invention do not include those known in the art to be too unstable to synthesize and / or isolate. The present invention is meant to include compounds in racemic and optically pure form. Optically active (R)- and (S)- or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. Where compounds described herein contain olefinic bonds or other geometrically asymmetric centers, unless otherwise specified, the compounds are intended to include both E and Z geometric isomers.
[0047] As used herein, the term "isomers" refers to compounds having the same number and kinds of atoms, and therefore the same molecular weight, but differing with respect to the structural or stereochemical arrangement of the atoms.
[0048] The term "tautomer," as used herein, refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.
[0049] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, and all tautomeric forms of such compounds are within the scope of the invention.
[0050] Unless otherwise stated, structures depicted herein are meant to include all stereochemical forms of the structure, i.e., having R and S configurations for each asymmetric center. Accordingly, single stereochemical isomers, enantiomeric, and diastereomeric mixtures of the present compounds are within the scope of the invention.
[0051] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, a hydrogen is replaced by deuterium or tritium, or a carbon is replaced by 13 C or 14 Compounds having the present structures except for the substitution of C-rich carbons are within the scope of the invention.
[0052] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. 3 H), iodine-125( 125 I), or carbon-14 ( 14 The compounds may be radiolabeled with radioactive isotopes such as C. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
[0053] "Analog" and "analogue" are used interchangeably and according to their ordinary and unambiguous meaning within the realm of chemistry and biology to refer to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference compound") but differs in composition (e.g., by the replacement of an atom with an atom of a different element, or by the presence or replacement of a particular functional group with another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound), including its isomers. Thus, an analog is a compound that is similar or identical in function and appearance to the reference compound, but dissimilar or identical in structure or origin.
[0054] symbol
[0055] [ka] indicates the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.
[0056] In some embodiments, the compounds described herein include R 2 and / or multiple instances of other variables. In such embodiments, each variable may optionally be different and may be appropriately labeled to distinguish each group for further clarity. For example, each R 2 are different, these can be expressed as, for example, R 2.1 , R 2.2 , R 2.3 and / or R 2.4 It may also be called R 2 The definition of R 2.1 , R 2.2 , R 2.3 and / or R 2.4 It is assumed by R 2 Variables used within the definitions of and / or other variables that appear in multiple instances and are different may similarly be appropriately labeled to distinguish between groups for further clarity. In some embodiments, the compound is a compound described herein (e.g., in some aspects, in the embodiments, examples, claims, tables, schemes, figures, or drawings).
[0057] The terms "a" or "an," as used herein, mean one or more. In addition, the phrase "substituted with a" as used herein means that the specified group may be substituted with one or more of any or all of the listed substituents. For example, if a group (e.g., an alkyl or heteroaryl group) is an "unsubstituted C-C 20 When the group is "alkyl-substituted or unsubstituted 2-20 membered heteroalkyl," the group is selected from the group consisting of one or more unsubstituted C1-C 20It may contain alkyl and / or one or more unsubstituted 2-20 membered heteroalkyl groups.
[0058] When a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." When a moiety is R-substituted, the moiety is substituted with at least one R substituent, and each R substituent may optionally be different. For example, a moiety herein may be R 12 When R is substituted or unsubstituted alkyl, multiple R 12 Substituents may be attached to the alkyl moiety, and each R 12 The substituents may optionally be different. When an R-substituted moiety is substituted with multiple R substituents, each R substituent may be distinguished herein using a prime symbol ('), such as R', R'', etc. For example, a moiety may be substituted with R 12 A substituted or unsubstituted alkyl group, the portion of which is a plurality of R 12 If substituted with a substituent, multiple R 12 The substituent is R 12 ', R 12 '', R 12 In some embodiments, the number of R substituents is three. In some embodiments, the number of R substituents is two.
[0059] In some embodiments, the compounds described herein include R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 and / or multiple instances of other variables. In such embodiments, each variable may optionally be different and may be appropriately labeled to distinguish each group for further clarity. For example, each R 1 , R 2 , R 3, R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , R 12 , R 13 and / or R 14 are different, they can be written as, for example, R 1.1 , R 1.2 , R 1.3 , R 1.4 , R 2.1 , R 2.2 , R 2.3 , R 2.4 , R 3.1 , R 3.2 , R 3.3 , R 3.4 , R 4.1 , R 4.2 , R 4.3 , R 4.4 , R 5.1 , R 5.2 , R 5.3 , R 5.4 , R 6.1 , R 6.2 , R 6.3 , R 6.4 , R 7.1 , R 7.2 , R 7.3 , R 7.4 , R 9.1 , R 9.2 , R 9.3 , R 9.4 , R 10.1 , R 10.2 , R 10.3 , R 10.4 , R 11.1 , R 11.2 , R 11.3 , R 11.4 , R 12.1 , R 12.2 , R 12.3 , R 12.4 , R 13.1 , R 13.2 , R 13.3 , R 13.4 , R 14.1 , R 14.2 , R 14.3 and / or R 14.4 It may also be called R 1 The definition of R 1.1, R 1.2 , R 1.3 and / or R 1.4 It is assumed by R 2 The definition of R 2.1 , R 2.2 , R 2.3 and / or R 2.4 It is assumed by R 3 The definition of R 3.1 , R 3.2 , R 3.3 and / or R 3.4 It is assumed by R 4 The definition of R 4.1 , R 4.2 , R 4.3 and / or R 4.4 It is assumed by R 5 The definition of R 5.1 , R 5.2 , R 5.3 and / or R 5.4 It is assumed by R 6 The definition of R 6.1 , R 6.2 , R 6.3 and / or R 6.4 It is assumed by R 7 The definition of R 7.1 , R 7.2 , R 7.3 and / or R 7.4 It is assumed by R 9 The definition of R 9.1 , R 9.2 , R 9.3 and / or R 9.4 It is assumed by R 10 The definition of R 10.1 , R 10.2 , R 10.3 and / or R 10.4 It is assumed by R 11 The definition of R 11.1 , R 11.2 , R 11.3 and / or R 11.4 It is assumed by R 12 The definition of R 12.1 , R 12.2 , R 12.3 and / or R 12.4 It is assumed by R 13 The definition of R 13.1, R 13.2 , R 13.3 and / or R 13.4 It is assumed by R 14 The definition of R 14.1 , R 14.2 , R 14.3 and / or R 14.4 It is assumed by R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R 10 , R 11 , R 12 , R 13 and / or R 14 Variables used within the definitions and / or other variables that appear in multiple instances and are different may similarly be appropriately labeled to distinguish between groups for further clarity.
[0060] The description of the compounds of the present invention is limited by the principles of chemical bonding known to those skilled in the art.Therefore, when a group can be substituted by one or more of many substituents, such substitutions are selected to give compounds that are consistent with the principles of chemical bonding and are not inherently unstable and / or are known to those skilled in the art to be highly likely to be unstable under ambient conditions (e.g., aqueous, neutral, some known physiological conditions).For example, heterocycloalkyl or heteroaryl are connected to the rest of the molecule via ring heteroatoms according to the principles of chemical bonding known to those skilled in the art, thereby avoiding inherently unstable compounds.
[0061] Antibodies are large, complex molecules (molecular weight of about 150,000 or about 1320 amino acids) with a complex internal structure. A natural antibody molecule contains two identical pairs of polypeptide chains, each pair containing one light chain and one heavy chain. Each light and heavy chain in turn consists of two regions: a variable ("V") region, which is involved in binding to the target antigen, and a constant ("C") region, which interacts with other components of the immune system. The light and heavy chain variable regions join together in three-dimensional space to form the variable region that binds to the antigen (e.g., a receptor on the surface of a cell). Within each light or heavy chain variable region, there are three short segments (average 10 amino acids long) called complementarity determining regions ("CDRs"). The six CDRs in an antibody variable domain (three from the light chain and three from the heavy chain) fold together in three-dimensional space to form the actual antibody binding site that docks to the target antigen. The positions and lengths of the CDRs are precisely defined by Kabat, E. et al., Sequences of Proteins of Immunological Interest, USDepartment of Health and Human Services, 1983, 1987. The parts of the variable regions not included in the CDRs are called the framework ("FR") and form the environment for the CDRs.
[0062] The term "antibody" is used according to its commonly known meaning in the art. Antibodies exist, for example, as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests antibodies under the disulfide bonds of the hinge region to produce F(ab)'2 (which itself is bounded by disulfide bonds in the V domain). H -C H1The F(ab)'2 dimer may be converted to a Fab' monomer by reducing the F(ab)'2 under mild conditions to break the disulfide bond in the hinge region. The Fab' monomer is essentially a Fab with a portion of the hinge region (see Fundamental Immunology (Paul, ed., 3rd ed., 1993)). Although various antibody fragments are defined in terms of the digestion of an intact antibody, one skilled in the art will understand that such fragments may be synthesized de novo, either chemically or using recombinant DNA methodology. Thus, the term antibody as used herein includes antibody fragments produced by the modification of a whole antibody or antibody fragments synthesized de novo using recombinant DNA methodology (e.g., single chain Fv) or identified using a phage display library (see, e.g., McCafferty et al., Nature 348:552-554 (1990)).
[0063] For the preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp.77-96 in Monoclonal Antibodies and Cancer Therapy (1985)). A "monoclonal" antibody (mAb) refers to an antibody derived from a single clone. Techniques for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to generate antibodies against polypeptides of the invention. Transgenic mice or other organisms (e.g., other mammals) may also be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to a selected antigen (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).
[0064] The epitope of a mAb is the region of its antigen to which the mAb binds. Two antibodies bind to the same or overlapping epitopes if each competitively inhibits (blocks) the binding of the other antibody to the antigen. That is, a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antibody inhibits the binding of the other antibody by at least 30%, but preferably up to 50%, 75%, 90%, or 99%, as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one of the antibodies reduce or eliminate binding to the other antibody. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one of the antibodies reduce or eliminate binding to the other antibody.
[0065] Antibodies exist, for example, as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests antibodies under the disulfide bonds of the hinge region to form F(ab)'2 (a dimer of Fab, itself a light chain bound to VH-CH1 by a disulfide bond). F(ab)'2 dimers may be converted to Fab' monomers by reducing them under mild conditions to break the disulfide bonds of the hinge region. The Fab' monomer is essentially the antigen-binding site with a portion of the hinge region (see Fundamental Immunology (Paul, ed., 3rd ed., 1993)). Although the various antibody fragments are defined in terms of digestion of intact antibodies, one skilled in the art will understand that such fragments may also be synthesized de novo, either chemically or using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments produced by the modification of whole antibodies or antibody fragments synthesized de novo using recombinant DNA methodologies (e.g., single-chain Fvs) or those identified using a phage display library (see, e.g., McCafferty et al., Nature 348:552-554 (1990)).
[0066] Single chain variable fragments (scFv) are typically fusion proteins of the variable regions of immunoglobulin heavy (VH) and light (VL) chains, linked to a short linker peptide of 10 to about 25 amino acids. The linker is usually rich in glycine for flexibility and may also be rich in serine or threonine for solubility. The linker may link the N-terminus of VH to the C-terminus of VL, or vice versa.
[0067] For the preparation of suitable antibodies of the invention and for use according to the invention, e.g., recombinant antibodies, monoclonal antibodies or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2nd ed., 1986)). Genes encoding the heavy and light chains of the antibody of interest can be cloned from cells, e.g., genes encoding a monoclonal antibody can be cloned from a hybridoma and used to produce a recombinant monoclonal antibody. Gene libraries encoding the heavy and light chains of monoclonal antibodies can also be produced from hybridomas or plasma cells. Random combination of heavy and light chain gene products produces a large pool of antibodies with different antigen specificities (see, e.g., Kuby, Immunology (3rd ed., 1997)). Techniques for producing single chain antibodies or recombinant antibodies (U.S. Pat. No. 4,946,778; U.S. Pat. No. 4,816,567) can be adapted to produce antibodies against the polypeptides of the invention.Also, transgenic mice or other organisms such as mammals can be used to express humanized or human antibodies (see, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks et al., Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:845-51 (1996)). 14:826 (1996); and Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995)). Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to a selected antigen (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)). Antibodies may be bispecific, i.e., capable of recognizing two different antigens (see, e.g., WO 93 / 08829; Traunecker et al., EMBO J. 10:3655-3659 (1991); and Suresh et al., Methods in Enzymology 121:210 (1986)). The antibody may also be a heteroconjugate, such as two covalently linked antibodies, or an immunotoxin (see, for example, US Pat. No. 4,676,980, WO 91 / 00360; WO 92 / 200373 and EP 03089).
[0068] Methods for humanizing or primatizing non-human antibodies are well known in the art (see, e.g., U.S. Pat. Nos. 4,816,567; 5,530,101; 5,859,205; 5,585,089; 5,693,761; 5,693,762; 5,777,085; 6,180,370; 6,210,671; and 6,329,511; WO 87 / 02671; European Patent Application No. 0173494; Jones et al. (1986) Nature 321:522; and Verhoyen et al. (1988) Science 239:1534). Humanized antibodies are further described, for example, in Winter and Milstein (1991) Nature 349:293. Generally, humanized antibodies have one or more amino acid residues introduced into them from a source that is non-human. These non-human amino acid residues are often referred to as import residues, and are typically taken from an import variable domain. Humanization can be essentially performed according to the method of Winter and coworkers (e.g., Morrison et al., PNAS USA, 81:6851-6855 (1984); Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Morrison and Oi, Adv. Immunol., 44:65-92 (1988), Verhoeyen et al., Science 34:111-111 (1989)) by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. 239:1534-1536 (1988) and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992); Padlan, Molec. Immun., 28:489-498 (1991); Padlan, Molec. Immun., 31(3):169-217 (1994). Such humanized antibodies thus are chimeric antibodies (U.S. Pat. No. 4,816,567) in which substantially less than an intact human variable domain has been replaced by the corresponding sequence from a non-human species.In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are replaced by residues from analogous sites in rodent antibodies. For example, a polynucleotide comprising a first sequence encoding the framework region of a humanized immunoglobulin and a second sequence encoding the desired immunoglobulin complementarity determining region can be produced synthetically or by combining appropriate cDNA and genomic DNA segments. Human constant region DNA sequences can be isolated from a variety of human cells according to well-known methods.
[0069] A "chimeric antibody" is an antibody molecule in which (a) the constant region or a portion thereof has been altered, substituted or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and / or species, or to an entirely different molecule (e.g., an enzyme, toxin, hormone, growth factor, drug, etc.) that confers new properties to the chimeric antibody; or (b) the variable region or a portion thereof has been altered, substituted or exchanged with a variable region having a different or altered antigen specificity. Preferred antibodies of the invention and for use according to the invention include humanized and / or chimeric monoclonal antibodies.
[0070] Techniques for conjugating therapeutic agents to antibodies are well known (see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery" in Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin (See, "Antibody-Drug Conjugates," Immunol. Rev., 62:119-58 (1982)). As used herein, the term "antibody-drug conjugate" or "ADC" refers to a therapeutic agent conjugated or otherwise covalently attached to an antibody. A "therapeutic agent" as referred to herein is a composition useful for treating or preventing a disease, such as cancer.
[0071] When referring to a protein or peptide, the phrases "specifically (or selectively) bind" or "specifically (or selectively) immunoreactive" to an antibody often refer to a binding reaction that determines the presence of the protein among a heterogeneous collection of proteins and other biologics. Thus, under specified immunoassay conditions, a particular antibody will bind to a particular protein at least twice background, and more typically more than 10-100 times background. Specific binding to an antibody under such conditions requires that the antibody be selected for its specificity for a particular protein. For example, polyclonal antibodies can be selected to obtain only a subset of antibodies that are specifically immunoreactive with a selected antigen and not specifically immunoreactive with other proteins. This selection may be accomplished by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats can be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual (1998), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
[0072] "Ligand" refers to an agent, such as a polypeptide or other molecule, that can bind to a receptor.
[0073] "Contacting" is used according to its ordinary meaning to refer to a process that allows at least two different species (e.g., chemical compounds, including biological molecules or cells) to come into sufficient proximity to react, interact, or come into physical contact. However, it should be understood that the resulting reaction product may be produced directly from the reaction between the added reagents, or may be produced from an intermediate that can be produced in the reaction mixture from one or more added reagents.
[0074] The term "contacting" can include reacting, interacting, or physically contacting two species, which can be, for example, a pharmaceutical composition as provided herein. In embodiments, contacting can include, for example, interacting a pharmaceutical composition as provided herein with a cell or a patient.
[0075] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. See, for example, Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989). Any methods, devices and materials similar or equivalent to those described herein can be used in the practice of the present invention. The following definitions are provided to facilitate understanding of certain terms frequently used herein and are not intended to limit the scope of the present disclosure.
[0076] "Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single or double stranded form and their complements. The term "polynucleotide" refers to a linear sequence of nucleotides. The term "nucleotide" typically refers to one unit, i.e., monomer, of a polynucleotide. Nucleotides may be ribonucleotides, deoxyribonucleotides or modified versions thereof. Examples of polynucleotides contemplated herein include single and double stranded DNA, single and double stranded RNA (including siRNA), and hybrid molecules containing mixtures of single and double stranded DNA and RNA. Nucleic acid, as used herein, also refers to nucleic acids that have the same basic chemical structure as naturally occurring nucleic acids. Such analogs have modified sugars and / or modified ring substituents but retain the same basic chemical structure as naturally occurring nucleic acids. Nucleic acid mimetics refer to chemical compounds that have a structure that differs from the general chemical structure of nucleic acids but functions in a manner similar to naturally occurring nucleic acids. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs).
[0077] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, which in embodiments may be conjugated to a moiety that is not composed of amino acids. These terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of a corresponding naturally occurring amino acid, as well as to naturally occurring and non-naturally occurring amino acid polymers. A "fusion protein" refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.
[0078] The terms "peptidyl" and "peptidyl moiety" refer to a monovalent peptide.
[0079] The term "amino acid" refers to natural and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are subsequently modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an alpha carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group (e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium). Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that differs from the general chemical structure of an amino acid, but functions in a manner similar to a naturally occurring amino acid. The terms "non-naturally occurring amino acid" and "unnatural amino acid" refer to amino acid analogs, synthetic amino acids, and amino acid mimetics that are not found in nature.
[0080] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Similarly, nucleotides may be referred to by their commonly accepted single-letter codes.
[0081] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, "conservatively modified variants" refers to nucleic acids that code for the same or essentially the same amino acid sequence. Due to the degeneracy of the genetic code, many nucleic acid sequences will code for any given protein. For example, the codons GCA, GCC, GCG, and GCU all code for the amino acid alanine. Thus, at every position where alanine is specified by a codon, the codon can be changed to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one type of conservatively modified variation. Every nucleic acid sequence herein that codes for a polypeptide also describes every possible silent variation of the nucleic acid. Those skilled in the art will recognize that each codon in a nucleic acid (except AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan) can be modified to obtain a functionally identical molecule. Thus, each silent variation of a nucleic acid that codes for a polypeptide is implicit in each sequence described.
[0082] With respect to amino acid sequences, one of skill in the art will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence that alter, add, or delete a single amino acid or a small percentage of amino acids in the encoded sequence are "conservatively modified variants," in which the modification replaces an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, and do not exclude, the polymorphic variants, interspecies homologs, and alleles of the invention.
[0083] Each of the following eight groups contains amino acids that are conservative substitutions for one another: (1) Alanine (A), glycine (G). (2) Aspartic acid (D), glutamic acid (E). (3) Asparagine (N), Glutamine (Q). (4) Arginine (R), Lysine (K). (5) Isoleucine (I), leucine (L), methionine (M), and valine (V). (6) Phenylalanine (F), tyrosine (Y), tryptophan (W). (7) serine (S), threonine (T); and (8) Cysteine (C), methionine (M) (see, for example, Creighton, Proteins (1984)).
[0084] The terms "numbered with reference to" or "corresponding to", when used in the context of numbering a given amino acid or polynucleotide sequence, refer to the numbering of residues in the stated reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. An amino acid residue in a protein "corresponds" to a given residue if it occupies the same essential structural position in the protein as the given residue. Those skilled in the art will readily recognize the identity and location of residues that correspond to specific positions of a protein (e.g., ROR-1) in other proteins using different numbering systems. For example, by performing a simple sequence alignment with a protein (e.g., ROR-1), the identity and location of residues that correspond to specific positions of the protein are identified in other protein sequences that align to the protein. For example, if the selected residue occupies the same essential spatial or other structural relationship as the glutamic acid at position 138, then the selected residue in the selected protein corresponds to the glutamic acid at position 138. In some embodiments, when the selected proteins are aligned for maximum homology with a protein, a position in the aligned selected protein that aligns with glutamic acid 138 is said to correspond to glutamic acid 138. Instead of a primary sequence alignment, a three-dimensional structural alignment may be used, for example, when the structures of the selected proteins are aligned for maximum correspondence with glutamic acid at position 138, the overall structures are compared. In this case, the amino acid that occupies the same essential position in the structural model as glutamic acid 138 is said to correspond to the glutamic acid 138 residue.
[0085] "Percent sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, where a portion of the polynucleotide or polypeptide sequence in the comparison window may contain additions or deletions (e.g., gaps) as compared to the reference sequence (which does not contain additions or deletions) due to optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which an identical nucleic acid base or amino acid residue is present in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage sequence identity.
[0086] The term "identical" or percentage of "identity" in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that contain the same or a specified percentage of amino acid residues or nucleotides (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity over a specified region, over a comparison window, compared and aligned for maximum correspondence, or over a specified region as measured using one of the sequence comparison algorithms below, or by manual alignment and visual inspection). Such sequences are said to be "substantially identical". This definition also refers to the complement of a test sequence. Optionally, the identity exists over a region of at least about 50 nucleotides in length, or more preferably over a range of 100 to 500 or 1000 or more nucleotides in length.
[0087] For sequence comparison, typically one sequence acts as a reference sequence, and this sequence is compared with the test sequence.When using sequence comparison algorithm, test sequence and reference sequence are input into computer, subsequence coordinates are designated, and sequence algorithm program parameters are designated if necessary.Default program parameters can be used, or alternative parameters can be designated.The sequence comparison algorithm then calculates the percent sequence identity of the test sequence to the reference sequence based on the program parameters.
[0088] A "comparison window", as used herein, includes reference to, for example, a full length sequence or any one segment of a number of contiguous positions selected from the group consisting of 20 to 600, about 50 to about 200, or about 100 to about 150 amino acids or nucleotides, and after optimal alignment of the two sequences, a sequence may be compared to a reference sequence having the same number of contiguous positions. Sequence alignment methods for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).
[0089] One example of an algorithm suitable for determining percent sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms, described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (website: ncbi.nlm.nih.gov / ). This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short strings of length W in the query sequence that, when aligned with strings of the same length in the database sequences, match or satisfy some positive threshold score T. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds to initiate searches to find longer HSPs that contain them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score increases. For nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0) are used to calculate the cumulative score. For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction is stopped when the cumulative alignment score falls an amount X below the maximum achieved value. The cumulative score becomes zero or less due to the volume of one or more negatively scoring residue alignments or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) or 10, M=5, N=-4, and a comparison of both strands.For amino acid sequences, the BLASTP program uses as defaults a word length of 3, an expectation (E) of 10, the BLOSUM62 scoring matrix (Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915), alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and sequence comparisons.
[0090] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides a measure of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered to be similar to a reference sequence. The minimum sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
[0091] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with an antibody raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the sequences can be amplified using the same primers.
[0092] The term "isolated" when applied to proteins indicates that the proteins are essentially free from other cellular components with which they are naturally associated. This is preferably in a homogeneous state, but may be either a dry state or an aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. The term "purified" indicates that the protein gives rise to essentially one band in an electrophoretic gel. In particular, the term refers to a purity of at least 85%, more preferably at least 95%, and most preferably at least 99%.
[0093] The phrases "specifically (or selectively) bind" or "specifically (or selectively) immunoreactive" with an antibody, when referring to a protein or peptide, refer to a binding reaction that determines the presence of the protein among a heterogeneous collection of proteins and other biologics. Thus, under specified immunoassay conditions, a particular antibody will bind to a particular protein at least twice background and will not bind substantially in significant amounts to other proteins present in the sample. Typically, a specific or selective reaction will be at least twice background signal or noise, and more typically greater than 10 to 100 times background.
[0094] As used herein, "cell" refers to a cell that performs metabolic or other functions sufficient to store or replicate genomic DNA. Cells can be identified by methods well known in the art, including, for example, the presence of an intact membrane, staining with a particular dye, the ability to produce progeny, or, in the case of gametes, the ability to combine with a second gamete and produce viable progeny. Cells may include prokaryotic and eukaryotic cells. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells and cells of plant and animal origin, such as mammalian, insect (e.g., Spodoptera) and human cells.
[0095] As defined herein, the terms "inhibit," "inhibit," "inhibiting," and the like, with respect to protein-inhibitor (e.g., receptor antagonist or signal transduction pathway inhibitor) interactions, refer to negatively affecting (e.g., decreasing) the activity or function of a protein (e.g., decreasing the activity of a receptor or protein) relative to the activity or function of the protein in the absence of the inhibitor. In some embodiments, inhibition refers to the reduction of a disease (e.g., cancer) or symptoms of the disease. Thus, inhibition includes at least partially, partially or completely blocking a stimulus, reducing, preventing, or delaying activation, or inactivating, desensitizing, or downregulating the amount of signal transduction or enzymatic activity or protein (e.g., a receptor). Similarly, an "inhibitor" is a compound or protein that inhibits a receptor or another protein, for example, by binding, partial or total blocking, reducing, preventing, delaying, inactivating, desensitizing, or downregulating activity.
[0096] The term "BTK antagonist" as provided herein refers to a substance capable of inhibiting BTK activity relative to a control. The inhibited activity of BTK may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even less than the activity in a control. In certain cases, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more relative to a control. A BTK antagonist inhibits BTK activity, at least in part, by partially or completely blocking stimulation, reducing, preventing, or delaying activation, or inactivating, desensitizing, or downregulating BTK signaling or activity or amount, relative to the absence of the BTK antagonist.
[0097] The term "ROR-1 antagonist" as provided herein refers to a substance capable of inhibiting ROR-1 activity as compared to a control. The inhibited activity of ROR-1 may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even less than the activity in the control. In certain cases, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more as compared to the control. ROR-1 antagonists inhibit ROR-1 activity at least in part by partially or completely blocking stimulation, reducing, preventing or delaying activation, or inactivating, desensitizing or downregulating ROR-1 signaling or activity or amount as compared to the absence of the ROR-1 antagonist. In some embodiments, the ROR-1 antagonist is an antibody or a small molecule.
[0098] The term "antagonist" may be used herein in place of inhibitor.
[0099] "Therapeutically effective dose or amount" as used herein means a dose that produces the effect for which it is administered (e.g., treat or prevent a disease). The actual dosage and formulation will depend on the purpose of the treatment and can be ascertained by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, Editor (2003) and Pickar, Dosage Calculations (1999)). For example, for a given parameter, a therapeutically effective amount will exhibit an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount may have at least 1.2-fold, 1.5-fold, 2-fold, 5-fold or more efficacy over a standard control. A therapeutically effective dose or amount may alleviate one or more symptoms of a disease. A therapeutically effective dose or amount may prevent or delay the onset of a disease or one or more symptoms of a disease when the effect administered is to treat a person at risk of developing a disease.
[0100] Somatomedin binding proteins;Sonermin;Sparfosic acid;Spicamycin D;Spiromustine;Splenopentin;Spongistatin 1;Squalamine;Stem cell inhibitors;Stem cell division inhibitors;Stipiamide;Stromalysin inhibitors;Sulfinosine;Superactive vasoactive intestinal peptide antagonists;Sladista;Suramin;Swainsonine;Synthetic glycosaminoglycans;Talimustine;Tamoxifen methiodide;Tauromustine;Tazarotene;Tecogalan sodium;Tegafur;Terlapyrylium;Telomerase inhibitors;Temoporfin; Temozolomide;Teniposide;Tetrachlorodecaoxide;Tetrazomine;Taliblastine;Thiocoraline;Thrombopoietin;Thrombopoietin mimetics;Thymalfasin;Thymopoietin receptor agonists;Thymotrin;Thyroid-stimulating hormone;Ethyl etiopurinse;Tirapazamine;Titanocene dichloride;Topsentin;Toremifene;Pluripotent stem cell factor;Translation inhibitors;Tretinoin;Triacetyluridine;Triciribine;Trimetrexate;Triptorelin;Tropisetron;Turosteride;Tyrosine kinase inhibitors;Tyrophostin;UBC Inhibitors;Ubenimex;Urogenital sinus-derived growth inhibitor;Urokinase receptor antagonists;Vapreotide;Variolin B;Vector systems, red blood cell gene therapy;Veraresol;Veramine;Verdine;Verteporfin;Vinorelbine;Vinxartin;Vitaxin;Vorozole;Zanoteron;Zeniplatin;Zilascorub;Zinostatin stimalamer,Adriamycin,Dactinomycin,Bleomycin,Vinblastine,Cisplatin,Acivicin;Aclarubicin;Acodazole hydrochloride;Acronine;Adozelesin;Aldesleukin;Altretamine ;Ambomycin;Amethanthrone acetate;Aminoglutethimide;Amsacrine;Anastrozole;Anthramycin;Asparaginase;Asperlin;Azacitidine;Azetepa;Azotomycin;Batimastat;Benzodepa;Bicalutamide;Bisantrene hydrochloride;Bisnafide mesylate;Bizelesin;Bleomycin sulfate;Brequinar sodium;Bropirimine;Busulfan;Cactinomycin;Calsterone;Caracemide;Carbetimer;Carboplatin;Carmustine;Carubicin hydrochloride;Carzelesin;Cedefingol;Chlorambucil;Ciroremycin; Cladribine; Crisnatol mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin hydrochloride; Decitabine; Dexorumaplatin; Dezaguanine; Dezaguanine mesylate; Diazicon; Doxorubicin; Doxorubicin hydrochloride; Droloxifene; Droloxifene citrate; Drostanolone propionate; Dauzomycin; Edatrexate; Eflornithine hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropizine; Epirubicin hydrochloride; Elbrozole; Esorubicin hydrochloride; Estramustine ;Estramustine phosphate;Etanidazole;Etoposide;Etoposide phosphate;Etoprine;Fadrozole hydrochloride;Fazarabine;Fenretinide;Floxuridine;Fludarabine phosphate;Fluorouracil;Fluorocitabine;Fosquidone;Fostriecin sodium;Gemcitabine;Gemcitabine hydrochloride;Hydroxyurea;Idarubicin hydrochloride;Ifosfamide;Imofosine;Interleukin I1 (including recombinant interleukin II or rlLsub.2), interferon alpha-2a;Interferon alpha-2b;Interferon alpha- n1;interferon alpha-n3;interferon beta-1a;interferon gamma-1b;iproplatin;irinotecan hydrochloride;lanreotide acetate;letrozole;leuprolide acetate;liarozole hydrochloride;lometrexol sodium;lomustine;rosoxantrone hydrochloride;masoprocol;maytansine;mechlorethamine hydrochloride;megestrol acetate;melengestrol acetate;melphalan;menogaril;mercaptopurine;methotrexate;methotrexate sodium;metoprine;meturedepa;mitindomide;mitocalcin;mitochromine; Mitogillin;Mitomarcin;Mitomycin;Mitosper;Mitotane;Mitoxantrone hydrochloride;Mycophenolic acid;Nocodazole;Nogalamycin;Ormaplatin;Oxisuran;Pegaspargase;Periomycin;Pentamustine;Peplomycin sulfate;Perfosfamide;Pipobroman;Piposulfan;Piroxantrone hydrochloride;Plicamycin;Promestane;Porfimer sodium;Porfiromycin;Prednimustine;Procarbazine hydrochloride;Puromycin;Puromycin hydrochloride;Pyrazofurin;Riboprin;Logretimide;Safingol;Safingol hydrochloride;Semustine;Simtrazene;Sparfosate sodium;Sparsomycin;Spirogermanium hydrochloride;Spiromustine;Spiroplatin;Streptonigrin;Streptozotocin;Sulofenur;Tallysomycin;Tecogalan sodium;Tegafur;Teroxantrone hydrochloride;Temoporfin;Teniposide;Teroxylon;Testolactone;Thiamiprine;Thioguanine;Thiotepa;Tiazofurin;Tirapazamine;Toremifene citrate;Trestorone acetate;Triciribine phosphate;Trimetre oxetate; trimetrexate glucuronate; triptorelin; tuburozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglisinate sulfate; vinreulosine sulfate; vinorelbine tartrate; vinrocidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phase and / or modulate the production or stability of microtubules (e.g., Taxol; TM (i.e., paclitaxel), Taxotere TM, compounds containing a taxane skeleton, elbrozole (i.e., R-55104), dolastatin 10 (i.e., DLS-10 and NSC-376128), mibobulin isethionate (i.e., as CI-980), vincristine, NSC-639829, discodermolide (i.e., as NVP-XX-A-296), ABT-751 (Abbott, i.e., E-7010), altorhyrtins (e.g., altorhyrtin A and altorhyrtin C), spongistatins (e.g., spongistatin 1, spongistatin 2, spongistatin 3, spongistatin 4, spongistatin 5, spongistatin 6, spongistatin 7, spongistatin 8 and spongistatin 9), cemadotin hydrochloride (i.e., LU-103793 and NSC-D-669356), epothilones (e.g., epothilone A, epothilone B, epothilone C (i.e., desoxyepothilone A or dEpoA), epothilone D (i.e., KOS-862, dEpoB and desoxyepothilone B), epothilone E, epothilone F, epothilone B N-oxide, epothilone AN-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e., BMS-310705), 21-hydroxyepothilone D (i.e., desoxyepothilone F and dEpoF), 26-fluoroepothilone, auristatin PE (i.e., NSC-654663), sobridotin (i.e., TZT-1027), vincristine sulfate, cryptophycin 52 (i.e., LY-355703), bitilebuamide, tubulisin A, kale, Nadensol, centaureydin (i.e., NSC-106969), oncocidin A1 (i.e., BTO-956 and DIME), physianolide B, laulimalide, narcosine (also known as NSC-5366), nascapine, hemiasterin, vanadocene acetylacetonate, monsatrol, inanosine (i.e., NSC-698666), eloterobin (e.g., resmethyleloterobin, desethyleloterobin, isoerobin, steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH), e.g., goserelin or leuprolide, adrenal cortices, Steroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caprylate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogens (e.g., flutamide), immunostimulants (e.g., BacillusCalmette-Guerin (BCG), levamisole, interleukin-2, α-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., 111 In, 90 Y or 131 anti-CD20 monoclonal antibodies conjugated to IFN-I or the like), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR) targeted therapies or therapeutic agents (e.g., gefitinib (Iressa TM ), erlotinib (Tarceva TM ), cetuximab (Erbitux TM ), lapatinib (Tykerb TM ), panitumumab (Vectibix TM ), vandetanib (Caprelsa TM ), afatinib / BIBW2992, CI-1033 / canertinib, neratinib / HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib / PF299804, OSI-420 / desmethylerlotinib, AZD8931, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, hormone therapy, etc.
[0101] The term "ibrutinib", also known as Imbruvica®, PCI 32765, etc., refers in its ordinary and common sense to 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-one-1-one (CAS Registry Number 936563-96-1). In some embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent Nos. 7,514,444; 8,008,309; 8,497,277; 8,476,284; 8,697,711; 8,703,780, the entireties of which are incorporated herein by reference for all purposes.
[0102] The term "idelalisib", also known as CAL101, GS-1101, Zydelig®, etc., refers in its ordinary and common sense to 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone (CAS Registry Number 870281-82-6). In some embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent Nos. 9,469,643; 9,492,449; 8,139,195; 8,492,389; 8,865,730; 9,149,477, the entireties of which are incorporated herein by reference for all purposes.
[0103] Terms such as "R406" refer in their normal and ordinary sense to 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one benzenesulfonate.
[0104] Terms such as "fostamatinib" refer in their ordinary and common sense to 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one benzenesulfonate (CAS Registry Number 901119-35-5 or 1025687-58-4 (disodium salt)). Fostamatinib is a prodrug of R406. In embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent No. 7,449,458, which is incorporated herein by reference in its entirety for all purposes.
[0105] The term "acalabrutinib", also known as ACP-196, refers in its ordinary and common sense to 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide (CAS Registry Number 1420477-60-6). In some embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent Application Nos. 20140155385, 20160151364, and 20160159810, the entireties of which are incorporated by reference herein for all purposes.
[0106] Terms such as "ONO / GS-4059" refer in their ordinary and common sense to 6-amino-7-(4-phenoxyphenyl)-9-[(3S)-1-prop-2-enoylpiperidin-3-yl]purin-8-one (CAS Registry Number 1351636-18-4). In embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent Nos. 8,940,725 and 8,557,803, U.S. Patent Application No. 20150094299, which are incorporated by reference herein in their entireties for all purposes.
[0107] Terms such as "BGB-3111" refer in their normal and common sense to 2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (CAS Registry Number 1633350-06-7). In embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent Application Nos. 20150259354 and 20160083392, which are incorporated by reference in their entireties for all purposes.
[0108] Terms such as "CC-292," also known as AVL-292, spebrutinib, and the like, refer in their normal, common sense to N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide (CAS Registry Number 1202757-89-8). In embodiments, the BTK antagonist is any one of the compounds disclosed in U.S. Patent No. 8,338,439, which is incorporated by reference herein in its entirety for all purposes.
[0109] The terms "cirmutuzumab," "UC-961," and "99961.1" refer to a humanized monoclonal antibody capable of binding to the extracellular domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR-1). In embodiments, cirmutuzumab is any one of the antibodies or fragments thereof disclosed in U.S. Patent Application No. 14 / 422,519, which is incorporated by reference in its entirety for all purposes.
[0110] As used herein, the term "about" refers to a range of values inclusive of the stated value, which one of ordinary skill in the art would consider to be reasonably similar to the stated value. In some embodiments, about refers to within a standard deviation using measurements generally accepted in the art. In some embodiments, about refers to a range extending to ±10% of the stated value. In some embodiments, about refers to the stated value.
[0111] The term "disease" or "condition" refers to the state or health of a patient or subject that can be treated with the compounds, pharmaceutical compositions, or methods provided herein. In some embodiments, the disease is cancer (e.g., lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma). The disease may be an autoimmune, inflammatory, cancerous, infectious, metabolic, developmental, cardiovascular, hepatic, intestinal, endocrine, neurological, or other disease.
[0112] As used herein, the term "cancer" refers to any type of cancer, neoplasm, or malignant tumor found in a mammal, including leukemia, lymphoma, melanoma, neuroendocrine tumors, carcinoma, and sarcoma. Exemplary cancers that may be treated with the compounds, pharmaceutical compositions, or methods provided herein include lymphoma, sarcoma, bladder cancer, bone cancer, brain cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., triple negative, ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, and the like. , prostate cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung cancer, squamous cell lung cancer, adenocarcinoma, large cell lung cancer, small cell lung cancer, carcinoid, sarcoma), glioblastoma multiforme, glioma, melanoma, prostate cancer, castration-resistant prostate cancer, breast cancer, triple-negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck or esophageal), colorectal cancer, leukemia, acute myeloid leukemia, lymphoma, B-cell lymphoma, or multiple myeloma. Further examples include thyroid cancer, endocrine system cancer, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, stomach cancer, uterine cancer or medulloblastoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulinoma. cancer, malignant carcinoid, bladder cancer, precancerous skin lesions, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical carcinoma, pancreatic endocrine or exocrine neoplasms, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, colorectal carcinoma, papillary thyroid cancer, hepatocellular carcinoma, Paget's disease of the papilla, phyllodes tumor, lobular carcinoma, ductal carcinoma, pancreatic stellate cell carcinoma, hepatic stellate cell carcinoma, or prostate cancer.
[0113] The term "leukemia" broadly refers to progressive malignant diseases of the blood-forming organs and is generally characterized by a distortion of the proliferation and development of white blood cells and their precursors in the blood and bone marrow. Leukemias are generally classified clinically on the basis of (1) the duration and character of the disease, whether acute or chronic, (2) the type of cell involved; bone marrow (myeloid), lymphocytes (lymphoid), or monocytic; and (3) the presence or absence of increased numbers of abnormal cells in the blood leukemia or non-leukemia (subleukemic). Exemplary leukemias that may be treated with the compounds, pharmaceutical compositions, or methods provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, non-leukemic leukemia, leukemic leukemia, basophilic leukemia, blastic leukemia, bovine leukemia, chronic myeloid leukemia, leukemia cutis, embryonic cell leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hemoblastic leukemia, hemoblastic cell leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogeneic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, small myeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelogenous leukemia, myelogranulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling leukemia, stem cell leukemia, subleukemic leukemia, or anaplastic cell leukemia.
[0114] The term "sarcoma" refers broadly to tumors formed in a substance like the connective tissue of the embryo and generally composed of closely packed cells embedded in fibrils or similar material. Exemplary sarcomas that may be treated with the compounds, pharmaceutical compositions, or methods provided herein include chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abernethy sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastoma, botryoid sarcoma, chlorosarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abernethy sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastoma, botryoid sarcoma, chlorosarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibro ... Examples of such sarcoma include sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple chromatohemorrhagic sarcoma, B-cell immunoblastic sarcoma, lymphoma, T-cell immunoblastic sarcoma, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukemia sarcoma, malignant mesenchymal sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serous bursal sarcoma, synovial sarcoma, and telangiectatic sarcoma.
[0115] The term "melanoma" is used to mean a tumor arising from the melanocytic system of the skin and other tissues. Melanomas that may be treated with the compounds, pharmaceutical compositions, or methods provided herein include, for example, acral lentigo melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungual melanoma, or superficial spreading melanoma.
[0116] The term "carcinoma" refers to a malignant neoplasm formed of epithelial cells that is prone to invade surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with the compounds, pharmaceutical compositions, or methods provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, adenocarcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma of the adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basal cell carcinoma, basaloid cell carcinoma, basosquamous cell carcinoma, bronchioloalveolar carcinoma, bronchiolocarcinoma, bronchogenic carcinoma, cerebrioid carcinoma, cholangiocellular carcinoma, choriocarcinoma, colloid carcinoma. , comedocarcinoma, corpus carcinoma, cribriform carcinoma, carcinoma of the torso, kutanoim carcinoma, columnar carcinoma, columnar cell carcinoma, ductal carcinoma, ductal carcinoma, durum carcinoma, embryonal carcinoma, encephalo-like carcinoma, epithelial adeno-like carcinoma, exophytic carcinoma, ulcerative carcinoma, fibrous carcinoma, gelatinous carcinoma, gelatinoid carcinoma, giant cell carcinoma, giant cell carcinoma, adenocarcinoma, granulosa cell carcinoma, hair matrix carcinoma, blood-like carcinoma, hepatocellular carcinoma, Hürthle cell carcinoma, hyaline carcinoma, adrenal-like carcinoma, Infantile embryonal carcinoma, carcinoma in situ, carcinoma in epidermis, carcinoma in situ, Kronpecher carcinoma, Kulchytsky cell carcinoma, large cell carcinoma, lenticular carcinoma, lenticular carcinoma, lipomatous carcinoma, lobular carcinoma, lymphoepithelial carcinoma, myeloid carcinoma, medullary carcinoma, melanoma, molar carcinoma, mucinous carcinoma, mucosal carcinoma, mucinous cell carcinoma, mucinous epidermoid carcinoma, mucosal carcinoma, mucinous carcinoma, myxomatous carcinoma, nasopharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, periportal carcinoma carcinoma, premetastatic carcinoma, squamous cell carcinoma, medullary carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatoid carcinoma, Schneider's carcinoma, scirrhous carcinoma, scrotal carcinoma, signet ring cell carcinoma, simplex carcinoma, small cell carcinoma, solanoid carcinoma, globular cell carcinoma, spindle cell carcinoma, cavernous carcinoma, lepidic carcinoma, squamous cell carcinoma, string carcinoma, telangiectatic carcinoma, telangiectatic carcinoma, transitional cell carcinoma, nodular carcinoma, tubular carcinoma, nodular carcinoma, verrucous carcinoma or choriocarcinoma.
[0117] As used herein, the terms "metastasis", "metastatic" and "metastatic cancer" can be used interchangeably and refer to the spread of a proliferative disease or disorder (e.g., cancer) from one organ or another non-adjacent organ or part of the body. Cancer begins at a primary site, e.g., the breast, and this site is called the primary tumor, e.g., primary breast cancer. Some cancer cells in the primary tumor or primary site acquire the ability to penetrate and invade the normal tissue surrounding the local area and / or penetrate the walls of the lymphatic or vascular system through which they circulate to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of the primary tumor is called a metastatic or secondary tumor. When cancer cells metastasize, the metastatic tumor and its cells are presumed to be similar to those of the original tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the breast site will consist of abnormal lung cells and will not contain abnormal breast cells. A secondary tumor in the chest is called metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or has had a primary tumor, and has one or more secondary tumors.The phrase non-metastatic cancer or a subject with a cancer that is not metastatic refers to a disease in which a subject has a primary tumor, but does not have one or more secondary tumors.For example, metastatic lung cancer refers to a disease in a subject that has or has a history of a primary lung tumor, and has one or more secondary tumors in a second location or multiple locations, for example, in the breast.
[0118] The term "associated with" or "associated with," in the context of a substance or an activity or function of a substance associated with a disease (e.g., diabetes, cancer (e.g., prostate cancer, kidney cancer, metastatic cancer, melanoma, castration-resistant prostate cancer, breast cancer, triple-negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (head, neck, or esophageal), colorectal cancer, leukemia, acute myeloid leukemia, lymphoma, B-cell lymphoma, or multiple myeloma), means that the substance or the activity or function of the substance causes (in whole or in part) the disease (e.g., lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma) or causes (in whole or in part) a symptom of the disease.
[0119] "Patient" or "subject in need thereof" refers to an organism suffering from or prone to a disease or condition that can be treated by administering a composition or pharmaceutical composition provided herein. Non-limiting examples include humans, other mammals, cows, rats, mice, dogs, monkeys, goats, sheep, cattle, deer, and other non-mammals. In some embodiments, the patient is a human.
[0120] method The methods provided herein are useful, inter alia, for the treatment of cancer. In embodiments, the methods and compositions described herein provide an effective treatment of cancers that express ROR-1. In one aspect, a method of treating cancer in a subject in need thereof is provided, the method comprising administering to the subject a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a tyrosine kinase-like orphan receptor 1 (ROR-1) antagonist.
[0121] In another aspect, a method of treating cancer in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and an anti-ROR-1 antibody.
[0122] The term "Bruton's tyrosine kinase", also known as tyrosine protein kinase BTK, as used herein refers to either recombinant or naturally occurring forms of Bruton's tyrosine kinase (BTK), or variants or homologs thereof that maintain BTK activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to BTK). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150 or 200 contiguous amino acids) compared to a naturally occurring BTK protein. In some embodiments, the BTK protein is substantially identical to or is a variant or homolog having substantial identity to a protein identified by UniProt Reference No. Q01687.
[0123] In some embodiments, the BTK antagonist is a small molecule. In some embodiments, the BTK antagonist is ibrutinib, idelalisib, fostamatinib, acalabrutinib, ONO / GS-4059, BGB-3111, or CC-292 (AVL-292). In some embodiments, the BTK antagonist is ibrutinib. In some embodiments, the BTK antagonist is idelalisib. In some embodiments, the BTK antagonist is fostamatinib. In some embodiments, the BTK antagonist is acalabrutinib. In some embodiments, the BTK antagonist is ONO / GS-4059. In some embodiments, the BTK antagonist is BGB-3111. In some embodiments, the BTK antagonist is CC-292 (AVL-292). In embodiments, the BTK antagonist is R406.
[0124] The term "ROR-1" as provided herein refers to either recombinant or naturally occurring forms of tyrosine kinase-like orphan receptor 1 (ROR-1) or variants or homologs thereof that maintain ROR-1 activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to ROR-1). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150 or 200 contiguous amino acids) compared to a naturally occurring ROR-1 protein. In some embodiments, the ROR-1 protein is substantially identical to or is a variant or homolog having substantial identity to a protein identified by Accession No. NP_005003.1. In embodiments, the ROR-1 protein comprises the amino acid sequence of SEQ ID NO: 13. In embodiments, the ROR-1 protein is the amino acid sequence of SEQ ID NO: 13. In embodiments, the ROR-1 protein comprises the amino acid sequence of SEQ ID NO: 14. In embodiments, the ROR-1 protein comprises the amino acid sequence of SEQ ID NO: 15.
[0125] When the ROR-1 antagonist is an antibody, the antibody specifically binds to the ROR-1 polypeptide. Thus, in some embodiments, the ROR-1 antagonist is an anti-ROR-1 antibody. In some embodiments, the anti-ROR-1 antibody is a humanized antibody.
[0126] An anti-ROR-1 antibody may comprise an amino acid sequence capable of binding to a portion of a ROR-1 polypeptide or a fragment thereof (e.g., CDRs). Thus, in some embodiments, the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region, the humanized heavy chain variable region comprising the sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and the humanized light chain variable region comprising the sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
[0127] In embodiments, the antibody is cirumutuzumab. Sirmutuzumab as defined herein is also referred to herein as UC-961 or 99961.1. The development and structure of cirumutuzumab is disclosed in U.S. Patent Application No. 14 / 422,519, which is incorporated by reference in its entirety for all purposes.
[0128] In embodiments, the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region, wherein the humanized heavy chain variable region comprises the sequences set forth in SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, and the humanized light chain variable region comprises the sequences set forth in SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12. An antibody comprising the amino acid sequences (i.e., CDRs) set forth by SEQ ID NOs:7, 8, 9, 10, 11, 12 may be referred to herein as antibody D10. The development and structure of antibody D10 is disclosed in U.S. Patent No. 9,217,040, which is incorporated by reference herein in its entirety for all purposes.
[0129] In some embodiments, the antibody binds to ROR-1 amino acids 130-160 or a fragment thereof. In some embodiments, the antibody binds to a peptide containing a glutamic acid at a position corresponding to position 138 of ROR-1. In some embodiments, the antibody specifically binds to either the 3' end or the central Ig-like region of the extracellular domain of the ROR-1 protein. In some embodiments, the antibody binds to the 3' end of the Ig-like region of the extracellular domain of the ROR-1 protein, from positions 1-147.
[0130] In embodiments, the antibody inhibits metastasis. In embodiments, the antibody is an antibody fragment. In embodiments, the antibody is a human antibody. In embodiments, the antibody is humanized. In embodiments, the antibody is a chimeric antibody. In embodiments, the antibody is a single light chain antibody.
[0131] In some embodiments, the antibody has a binding affinity of about 500 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 550 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 600 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 650 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 700 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 750 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 800 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 850 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 900 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 950 pM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 1 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 1 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 1.5 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 2 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 2.5 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 3 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 3.5 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 4 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 4.5 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 5 nM to about 6 nM. In some embodiments, the antibody has a binding affinity of about 5.5 nM to about 6 nM.
[0132] In some embodiments, the antibody has a binding affinity of 500 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 550 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 600 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 650 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 700 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 750 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 800 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 850 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 900 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 950 pM to 6 nM. In some embodiments, the antibody has a binding affinity of 1 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 1 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 1.5 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 2 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 2.5 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 3 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 3.5 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 4 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 4.5 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 5 nM to 6 nM. In some embodiments, the antibody has a binding affinity of 5.5 nM to 6 nM.
[0133] In some embodiments, the antibody has a binding affinity of about 500 pM to about 5.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 4.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 4 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 3.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 3 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 3.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 3 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 2.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 2 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 1.5 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 1 nM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 950 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 900 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 850 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 800 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 750 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 700 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 650 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 600 pM. In some embodiments, the antibody has a binding affinity of about 500 pM to about 550 pM.
[0134] In some embodiments, the antibody has a binding affinity of 500 pM to 5.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 4.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 4 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 3.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 3 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 3.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 3 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 2.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 2 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 1.5 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 1 nM. In some embodiments, the antibody has a binding affinity of 500 pM to 950 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 900 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 850 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 800 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 750 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 700 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 650 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 600 pM. In some embodiments, the antibody has a binding affinity of 500 pM to 550 pM.
[0135] In some embodiments, the antibody has a binding affinity of about 500 pM. In some embodiments, the antibody has a binding affinity of 500 pM. In some embodiments, the antibody has a binding affinity of about 550 pM. In some embodiments, the antibody has a binding affinity of 550 pM. In some embodiments, the antibody has a binding affinity of about 600 pM. In some embodiments, the antibody has a binding affinity of 600 pM. In some embodiments, the antibody has a binding affinity of about 650 pM. In some embodiments, the antibody has a binding affinity of 650 pM. In some embodiments, the antibody has a binding affinity of about 700 pM. In some embodiments, the antibody has a binding affinity of 700 pM. In some embodiments, the antibody has a binding affinity of about 750 pM. In some embodiments, the antibody has a binding affinity of 750 pM. In some embodiments, the antibody has a binding affinity of about 800 pM. In some embodiments, the antibody has a binding affinity of 800 pM. In some embodiments, the antibody has a binding affinity of about 850 pM. In some embodiments, the antibody has a binding affinity of 850 pM. In some embodiments, the antibody has a binding affinity of about 900 pM. In some embodiments, the antibody has a binding affinity of 900 pM. In some embodiments, the antibody has a binding affinity of about 950 pM. In some embodiments, the antibody has a binding affinity of 950 pM. In some embodiments, the antibody has a binding affinity of about 1 nM. In some embodiments, the antibody has a binding affinity of about 1 nM. In some embodiments, the antibody has a binding affinity of about 1.5 nM. In embodiments, the antibody has a binding affinity of 1.5 nM. In embodiments, the antibody has a binding affinity of about 2 nM. In embodiments, the antibody has a binding affinity of 2 nM. In embodiments, the antibody has a binding affinity of about 2.5 nM. In embodiments, the antibody has a binding affinity of 2.5 nM. In embodiments, the antibody has a binding affinity of about 3 nM. In embodiments, the antibody has a binding affinity of 3 nM.In embodiments, the antibody has a binding affinity of about 3.5 nM. In embodiments, the antibody has a binding affinity of 3.5 nM. In embodiments, the antibody has a binding affinity of about 4 nM. In embodiments, the antibody has a binding affinity of 4 nM. In embodiments, the antibody has a binding affinity of about 4.5 nM. In embodiments, the antibody has a binding affinity of 4.5 nM. In embodiments, the antibody has a binding affinity of about 5 nM. In embodiments, the antibody has a binding affinity of 5 nM. In embodiments, the antibody has a binding affinity of about 5.5 nM. In embodiments, the antibody has a binding affinity of 5.5 nM. In embodiments, the antibody has a binding affinity of about 6 nM. In embodiments, the antibody has a binding affinity of 6 nM.
[0136] In embodiments, the antibody has a K of less than about 40 nM (e.g., 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, 0.25, 0.1 nM). D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 40 nM (e.g., 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, 0.25, 0.1 nM). D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 35 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 35 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 30 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 30 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 25 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 25 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 20 nM. DIn some embodiments, the antibody binds to the ROR-1 protein with a K of less than 20 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 15 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 15 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 10 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 10 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 9 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 9 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 8 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 8 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 7 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 7 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 6 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 6 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 5 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 5 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 4 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 4 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 3 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 3 nM. DIn some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 2 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 2 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 1 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 1 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 0.5 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 0.5 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 0.25 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 0.25 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than about 0.1 nM. D In some embodiments, the antibody binds to the ROR-1 protein with a K of less than 0.1 nM. D It binds to the ROR-1 protein.
[0137] In embodiments, the antibody is cirumutuzumab, also referred to herein as 99961.1 or UC-961. In embodiments, the antibody is D10.
[0138] In some embodiments, the BTK antagonist and the ROR-1 antagonist are administered in a combined synergistic amount. In some embodiments, the BTK antagonist and the anti-ROR-1 antibody are administered in a combined synergistic amount. A "combined synergistic amount," as used herein, refers to the sum of a first amount (e.g., an amount of a BTK antagonist) and a second amount (e.g., an amount of a ROR-1 antagonist) that results in a synergistic effect (i.e., an effect that is greater than additive). Thus, the terms "synergy," "synergistic effect," "synergistic," "combined synergistic amount," and "synergistic therapeutic effect" are used interchangeably and refer to a measured effect of compounds administered in combination that is greater than the sum of the individual effects of each compound administered alone as a single agent.
[0139] In embodiments, a synergistic amount is about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.5, 9.6, 9.7, 9.8, 9.9, 10.1, 10. ,3.3,3.4,3.5,3.6,3.7,3.8,3.9,4.0,4.1,4.2,4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,5.1,5.2,5.3,5.4,5.5,5.6,5.7,5.8,5.9,6.0,6.1,6.2,6.3,6.4,6.5,6.6,6.7,6.8,6.9,7.0,7.1,7.2,7.3,7.4,7.5,7.6,7.7,7. 8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.In embodiments, a synergistic amount is about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.5, 9.6, 9.7, 9.8, 9.9, 10.1, 10. ,3.3,3.4,3.5,3.6,3.7,3.8,3.9,4.0,4.1,4.2,4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,5.1,5.2,5.3,5.4,5.5,5.6,5.7,5.8,5.9,6.0,6.1,6.2,6.3,6.4,6.5,6.6,6.7,6.8,6.9,7.0,7.1,7.2,7.3,7.4,7.5,7.6,7.7,7. 8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.
[0140] A synergistic effect can be an effect of reducing BTK activity and / or an effect of reducing ROR-1 activity. In embodiments, the synergy between the BTK antagonist and the ROR-1 antagonist reduces activity by about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9. ,2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8 ,7.9,8.0,8.1,8.2,8.3,8.4,8.5,8.6,8.7,8.8,8.9,9.0,9.1,9.2,9.3,9.4,9.5,9.6,9.7,9.8,9.9,10.0,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48, , 92, 93, 94, 95, 96, 97, 98, 99 or 100%, or more, decrease (e.g., decrease in BTK activity or decrease in ROR-1 activity).In embodiments, the synergy between the BTK antagonist and the ROR-1 antagonist may reduce or inhibit the activity of the BTK antagonist by about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.1, 10.2, .8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, In one embodiment, the method may result in 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% or more inhibition of BTK protein and / or ROR-1 protein.
[0141] Synergy can refer to an effect in treating cancer, for example, lymphoma (i.e., synergy in treating lymphoma), leukemia (i.e., synergy in treating leukemia), myeloma (i.e., synergy in treating myeloma), AML (i.e., synergy in treating AML), B-ALL (i.e., synergy in treating B-ALL), T-ALL (i.e., synergy in treating T-ALL), renal cell carcinoma (i.e., synergy in treating renal cell carcinoma), colon cancer (i.e., synergy in treating colon cancer), colorectal cancer (i.e., synergy in treating colon cancer), and the like. Cancer (i.e., synergy to treat colorectal cancer), breast cancer (i.e., synergy to treat breast cancer), squamous cell carcinoma (i.e., synergy to treat squamous cell carcinoma), melanoma (i.e., synergy to treat melanoma), gastric cancer (i.e., synergy to treat gastric cancer), brain cancer (i.e., synergy to treat brain cancer), lung cancer (i.e., synergy to treat lung cancer), pancreatic cancer (i.e., synergy to treat pancreatic cancer), cervical cancer (i.e., synergy to treat cervical cancer). synergy), ovarian cancer (i.e., synergy to treat ovarian cancer), liver cancer (i.e., synergy to treat liver cancer), bladder cancer (i.e., synergy to treat bladder cancer), prostate cancer (i.e., synergy to treat prostate cancer), testicular cancer (i.e., synergy to treat testicular cancer), thyroid cancer (i.e., synergy to treat thyroid cancer), head and neck cancer (i.e., synergy to treat head and neck cancer), uterine cancer (i.e., synergy to treat uterine cancer), adenocarcinoma (i.e., synergy to treat adenocarcinoma), The synergistic effect may be an effect in treating adrenal cancer (i.e., a synergistic effect in treating adrenal cancer), chronic lymphocytic leukemia (i.e., a synergistic effect in treating chronic lymphocytic leukemia), small lymphocytic lymphoma (i.e., a synergistic effect in treating small lymphocytic lymphoma), peripheral cell B-cell lymphoma (i.e., a synergistic effect in treating peripheral cell B-cell lymphoma), Burkitt's lymphoma (i.e., a synergistic effect in treating Burkitt's lymphoma), and B-cell leukemia (i.e., a synergistic effect in treating B-cell leukemia).
[0142] The BTK antagonist and the ROR-1 antagonist may be administered in combination simultaneously (e.g., as a mixture), separately but simultaneously (e.g., via separate intravenous lines), or sequentially (e.g., one agent is administered first, followed by the second agent). Thus, the term combination is used to refer to the combined, simultaneous, or sequential administration of the BTK antagonist and the ROR-1 antagonist.
[0143] In some embodiments, the BTK antagonist and the ROR-1 antagonist are administered simultaneously or sequentially. In some embodiments, the BTK antagonist and the ROR-1 antagonist are administered simultaneously. In some embodiments, the BTK antagonist and the ROR-1 antagonist are administered sequentially. During a course of treatment, the BTK antagonist and the ROR-1 antagonist may be administered sequentially at certain times and simultaneously at other times.
[0144] In some embodiments, when the BTK antagonist and the ROR-1 antagonist are administered sequentially, the ROR-1 antagonist is administered at a first time point and the BTK antagonist is administered at a second time point, the first time point being prior to the second time point, or, in some embodiments, when the BTK antagonist and the ROR-1 antagonist are administered sequentially, the BTK antagonist is administered at a first time point and the ROR-1 antagonist is administered at a second time point, the first time point being prior to the second time point.
[0145] In some embodiments, the BTK antagonist and the anti-ROR-1 antibody are administered simultaneously or sequentially. In some embodiments, the BTK antagonist and the anti-ROR-1 antibody are administered simultaneously. In some embodiments, the BTK antagonist and the anti-ROR-1 antibody are administered sequentially. During a course of treatment, the BTK antagonist and the anti-ROR-1 antibody may be administered sequentially at some times and simultaneously at other times.
[0146] In some embodiments, when the BTK antagonist and the anti-ROR-1 antibody are administered sequentially, the anti-ROR-1 antibody is administered at a first time point and the BTK antagonist is administered at a second time point, the first time point being prior to the second time point, or, in some embodiments, when the BTK antagonist and the anti-ROR-1 antibody are administered sequentially, the BTK antagonist is administered at a first time point and the anti-ROR-1 antibody is administered at a second time point, the first time point being prior to the second time point.
[0147] The course of treatment is best determined on an individual basis, depending on the specific characteristics of the subject and the type of treatment selected. Treatment as disclosed herein can be administered to the subject daily, twice daily, once every two weeks, once a month, or any applicable number of times effective for treatment. Treatment may be administered alone or in combination with other treatments disclosed herein or known in the art. The additional treatment can be administered at the same time as the first treatment, at a different time, or on an entirely different treatment schedule (e.g., the first treatment may be daily and the additional treatment once a week).
[0148] When the BTK antagonist and the ROR-1 antagonist are administered simultaneously, the BTK antagonist and the ROR-1 antagonist may be administered as a mixture, and thus, in some embodiments, the BTK antagonist and the ROR-1 antagonist are mixed prior to administration.
[0149] In some embodiments, the BTK antagonist is administered in an amount of about 1 mg / kg, 2 mg / kg, 5 mg / kg, 10 mg / kg, or 15 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 1 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 1 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 2 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 2 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 5 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 5 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 10 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 10 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 15 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 15 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 420 mg. In some embodiments, the BTK antagonist is administered in an amount of 420 mg.
[0150] In some embodiments, the ROR-1 antagonist is administered in an amount of about 1 mg / kg, 2 mg / kg, 3 mg / kg, 5 mg / kg, or 10 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of about 1 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of 1 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of about 2 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of 2 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of about 3 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of 3 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of about 5 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of 5 mg / kg. In some embodiments, the ROR-1 antagonist is administered in an amount of about 10 mg / kg.In some embodiments, the ROR-1 antagonist is administered in an amount of 10 mg / kg.
[0151] In some embodiments, the BTK antagonist is administered in an amount of about 5 mg / kg and the ROR-1 antagonist is administered at about 2 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 5 mg / kg and the ROR-1 antagonist is administered at 2 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of about 5 mg / kg and the ROR-1 antagonist is administered at about 1 mg / kg. In some embodiments, the BTK antagonist is administered in an amount of 5 mg / kg and the ROR-1 antagonist is administered at 1 mg / kg.
[0152] In some embodiments, the BTK antagonist is administered daily for at least 14 days (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 45, or 50 days). In some embodiments, the BTK antagonist is administered daily for at least 15 days. In some embodiments, the BTK antagonist is administered daily for at least 16 days. In some embodiments, the BTK antagonist is administered daily for at least 17 days. In some embodiments, the BTK antagonist is administered daily for at least 18 days. In some embodiments, the BTK antagonist is administered daily for at least 19 days. In some embodiments, the BTK antagonist is administered daily for at least 20 days. In some embodiments, the BTK antagonist is administered daily for at least 21 days. In some embodiments, the BTK antagonist is administered daily for at least 22 days. In some embodiments, the BTK antagonist is administered daily for at least 23 days. In some embodiments, the BTK antagonist is administered daily for at least 24 days. In some embodiments, the BTK antagonist is administered daily for at least 25 days. In some embodiments, the BTK antagonist is administered daily for at least 26 days. In some embodiments, the BTK antagonist is administered daily for at least 27 days. In some embodiments, the BTK antagonist is administered daily for at least 28 days. In some embodiments, the BTK antagonist is administered daily for at least 29 days. In some embodiments, the BTK antagonist is administered daily for at least 30 days. In some embodiments, the BTK antagonist is administered daily for at least 31 days. In some embodiments, the BTK antagonist is administered daily for at least 32 days. In some embodiments, the BTK antagonist is administered daily for at least 33 days.In some embodiments, the BTK antagonist is administered daily for at least 34 days. In some embodiments, the BTK antagonist is administered daily for at least 35 days. In some embodiments, the BTK antagonist is administered daily for at least 40 days. In some embodiments, the BTK antagonist is administered daily for at least 45 days. In some embodiments, the BTK antagonist is administered daily for at least 50 days.
[0153] In some embodiments, the BTK antagonist is administered daily for about 28 days. In some embodiments, the BTK antagonist is administered daily for about 28 days.
[0154] In some embodiments, the ROR-1 antagonist is administered once over a period of about 28 days. In some embodiments, the ROR-1 antagonist is administered once over a period of about 28 days.
[0155] In some embodiments, the BTK antagonist is administered intravenously. In some embodiments, the ROR-1 antagonist is administered intravenously.
[0156] In some embodiments, the subject is a mammal, hi some embodiments, the subject is a human.
[0157] As described above, the methods and compositions provided herein, including embodiments thereof, are useful for treating cancer, and in particular, cancers that express ROR-1. In some embodiments, the cancer is lymphoma, leukemia, myeloma, AML, B-ALL, T-ALL, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, head and neck cancer, uterine cancer, adenocarcinoma, or adrenal cancer. In some embodiments, the cancer is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, peripheral cell B-cell lymphoma, Burkitt's lymphoma, or B-cell leukemia.
[0158] The combination of BTK antagonists and ROR-1 antagonists administered as provided herein, including embodiments thereof, may vary. For example, a specific BTK antagonist (e.g., ibrutinib) may be administered in combination with a specific ROR-1 antagonist (e.g., cirumutuzumab). Thus, in some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumutuzumab. In some embodiments, the BTK antagonist idelalisib is administered in combination with the ROR-1 antagonist cirumutuzumab. In some embodiments, the BTK antagonist fostamatinib is administered in combination with the ROR-1 antagonist cirumutuzumab. In some embodiments, the BTK antagonist acalabrutinib is administered in combination with the ROR-1 antagonist cirumutuzumab. In some embodiments, the BTK antagonist ONO / GS-4059 is administered in combination with the ROR-1 antagonist cirumtuzumab. In some embodiments, the BTK antagonist BGB-3111 is administered in combination with the ROR-1 antagonist cirumtuzumab. In some embodiments, the BTK antagonist CC-292 (AVL-292) is administered in combination with the ROR-1 antagonist cirumtuzumab. In some embodiments, the BTK antagonist R406 is administered in combination with the ROR-1 antagonist cirumtuzumab.
[0159] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 1 mg / kg and cirumtuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0160] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 1 mg / kg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0161] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 1 mg / kg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0162] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 1 mg / kg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0163] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 1 mg / kg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0164] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 2 mg / kg and cirumtuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0165] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 2 mg / kg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0166] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 2 mg / kg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0167] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 2 mg / kg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0168] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 2 mg / kg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0169] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 5 mg / kg and cirumtuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0170] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 5 mg / kg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0171] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 5 mg / kg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0172] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 5 mg / kg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0173] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 5 mg / kg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0174] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 10 mg / kg and cirumtuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0175] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 10 mg / kg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0176] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 10 mg / kg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0177] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 10 mg / kg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0178] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 10 mg / kg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0179] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumutuzumab, where ibrutinib is administered intravenously in an amount of 15 mg / kg and cirumutuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumutuzumab is administered once for 28 days.
[0180] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 15 mg / kg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0181] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 15 mg / kg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0182] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 15 mg / kg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0183] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 15 mg / kg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0184] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 420 mg and cirumtuzumab is administered intravenously in an amount of 1 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0185] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 420 mg and cirumtuzumab is administered intravenously in an amount of 2 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0186] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 420 mg and cirumtuzumab is administered intravenously in an amount of 3 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0187] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 420 mg and cirumtuzumab is administered intravenously in an amount of 5 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0188] In some embodiments, the BTK antagonist ibrutinib is administered in combination with the ROR-1 antagonist cirumtuzumab, where ibrutinib is administered intravenously in an amount of 420 mg and cirumtuzumab is administered intravenously in an amount of 10 mg / kg. In a further embodiment, ibrutinib is administered daily for 28 days and cirumtuzumab is administered once for 28 days.
[0189] Pharmaceutical Compositions The compositions comprising the BTK antagonist and the ROR-1 antagonist provided herein, including embodiments thereof, are further contemplated as pharmaceutical compositions. Thus, in one aspect, a pharmaceutical composition is provided that comprises a BTK antagonist, a ROR-1 antagonist, and a pharma- ceutically acceptable excipient.
[0190] In another aspect, a pharmaceutical composition is provided that includes a Bruton's tyrosine kinase (BTK) antagonist, an anti-ROR-1 antibody, and a pharma- ceutically acceptable excipient. In embodiments, the BTK antagonist and the anti-ROR-1 antibody are present in a combined synergistic amount, and the combined synergistic amount is effective to treat cancer in a subject in need of such treatment.
[0191] The BTK antagonist and ROR-1 antagonist included in the pharmaceutical compositions provided herein may be any one of the BTK antagonists and / or ROR-1 antagonists described herein, including embodiments thereof. For example, the BTK antagonist may be ibrutinib, and the ROR-1 antagonist may be cirumtuzumab. Similarly, the pharmaceutical compositions provided herein may be formulated such that the administered amount of the BTK antagonist and the ROR-1 antagonist is any one of the amounts described herein. For example, ibrutinib may be present in an amount such that administration of the composition provides a dosage of about 5 mg / kg or 420 mg, and cirumtuzumab may be present in an amount such that a dosage of about 2 mg / kg is provided.
[0192] The provided compositions are suitable for formulation and administration, particularly in vitro or in vivo. Suitable carriers and excipients and their formulations are described in The Science and Practice of Pharmacy, 21st Edition, edited by David B. Troy, Lippicott Williams & Wilkins (2005). A pharmaceutically acceptable carrier means a substance that is not biologically or otherwise undesirable. That is, the substance is administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with other components of the pharmaceutical composition in which it is contained. When administered to a subject, the carrier is optionally selected to minimize the degradation of the active ingredient and to minimize adverse side effects in the subject.
[0193] Pharmaceutical compositions provided by the present invention include compositions in which the active ingredient (e.g., compositions described herein, including embodiments or examples) is contained in a therapeutically effective amount, i.e., an amount effective to achieve the intended purpose. The actual amount effective for a particular application will depend, among other things, on the condition being treated. When administered in a method for treating a disease, the recombinant proteins described herein will contain an amount of active ingredient effective to achieve the desired result (e.g., modulating the activity of a target molecule and / or reducing, eliminating, or slowing the progression of a disease symptom). Determination of a therapeutically effective amount of a compound of the present invention is well within the capabilities of one of ordinary skill in the art, especially in light of the detailed disclosure herein.
[0194] The compositions provided may contain a single agent or multiple agents. The compositions for administration generally contain the agents described herein dissolved in a pharma- ceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, such as buffered saline. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharma- cetically acceptable auxiliary substances necessary for appropriate physiological conditions, such as pH adjusting agents and buffers, toxicity adjusting agents, and the like, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and the like. The concentration of the active agent in these formulations may vary widely and is selected primarily based on bodily fluid volume, viscosity, body weight, and the like, depending on the particular mode of administration selected and the needs of the subject.
[0195] Solutions of the active compounds as free bases or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
[0196] The pharmaceutical composition can be delivered by intranasal or inhalable solutions or sprays, aerosols or inhalants. Nasal solutions can be aqueous solutions designed to be administered to the nasal cavity by nasal drops or sprays. Nasal solutions can be prepared to resemble nasal secretions in many respects. Thus, nasal aqueous solutions are usually isotonic and slightly buffered to maintain a pH of 5.5 to 6.5. In addition, antimicrobial preservatives similar to those used in ophthalmic formulations and suitable drug stabilizers may be included in the formulation, if necessary. A variety of commercially available nasal formulations are known and may contain, for example, antibiotics and antihistamines.
[0197] Oral formulations may contain excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders. In some embodiments, oral pharmaceutical compositions may contain an inert diluent or an assimilable edible carrier, or may be enclosed in hard or soft gelatin capsules, or may be compressed into tablets, or may be incorporated directly into edible food. For oral therapeutic administration, the active compound may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of the active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75%, preferably 25-60%, of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained.
[0198] For example, for parenteral administration in an aqueous solution, the solution should be suitably buffered and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. Aqueous solutions, particularly sterile aqueous media, are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. For example, one dose can be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion fluid or injected at the proposed injection site.
[0199] Sterile injectable solutions can be prepared by incorporating the required amount of active compound or construct in a suitable solvent, followed by sterilization by filtration. Generally, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium. Sterile powders for reconstituting sterile injectable solutions can be prepared using vacuum drying and freeze-drying techniques to obtain a powder of active ingredient and any additional desired ingredients. The preparation of more or highly concentrated solutions for direct injection is also envisioned. DMSO can be used as a solvent for very rapid penetration, delivering high concentrations of active agents to a small area.
[0200] The compound preparation can be provided in a unit-dose or multi-dose sealed container, such as ampoules and vials.Therefore, the composition can be in unit dosage form.In this form, the preparation is divided into unit dosages that contain an appropriate amount of active ingredient.Therefore, the composition can be administered in various unit dosage forms depending on the method of administration.For example, the unit dosage forms suitable for oral administration include, but are not limited to, powder, tablet, pill, capsule and lozenge.
[0201] The dosage and frequency (single or multiple doses) administered to a mammal may vary depending on a variety of factors, such as whether the mammal is suffering from another disease and the route of administration; the size, age, sex, health, weight, body mass index, body mass index and diet of the recipient; the nature and extent of the symptoms of the disease being treated (e.g., cancer symptoms and the severity of such symptoms); the type of concurrent treatment, complications due to the disease being treated or other health-related problems. Other treatment regimens or drugs can be used in conjunction with the methods and compounds of the present invention. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the capabilities of one of ordinary skill in the art.
[0202] For any composition described herein (e.g., cell-permeable conjugates provided), the therapeutically effective amount can be initially determined from cell culture assays. The target concentration is the concentration of active compound that can achieve the methods described herein when measured using the methods described herein or using methods known in the art. As is well known in the art, effective amounts for use in humans can also be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration known to be effective in animals. A dose for humans can be adjusted by monitoring efficacy and adjusting the dose upwards or downwards as described above. It is well within the capabilities of one of ordinary skill in the art to adjust the dose to achieve maximum efficacy in humans based on the methods described above and other methods.
[0203] Dosage may vary depending on the needs of the patient and the compound used. The dosage administered to the patient in the context of the present invention should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dosage will also be determined by the existence, nature and extent of adverse side effects. Determining the appropriate dosage for a particular situation is within the skill of the physician. Generally, treatment is initiated with smaller dosages that are lower than the optimal dosage of the compound. Dosage is then increased by small increments until the optimal effect under the circumstances is reached.
[0204] Dosage amount and interval can be adjusted individually to provide levels of the administered compound that are effective for the particular clinical indication being treated, thereby providing a treatment regimen commensurate with the severity of the individual's disease state.
[0205] Utilizing the teachings provided herein, one can design an effective prophylactic or therapeutic treatment regimen that does not cause substantial toxicity yet is effective in treating the clinical symptoms exhibited by a particular patient. This regimen requires careful selection of an active compound, taking into account factors such as the potency of the compound, its relative bioavailability, the patient's weight, the presence and severity of adverse side effects, and the like.
[0206] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to substances that aid in the effective administration of and absorption by a subject of a drug and that can be included in the compositions of the present invention without causing significant adverse toxic effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline, lactate Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coating agents, sweeteners, flavoring agents, salt solutions (e.g., Ringer's solution), alcohols, oils, gelatin, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidine, and dyes. Such preparations may be sterilized and mixed with auxiliary agents that do not adversely react with the compounds of the present invention, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, buffers, coloring agents, and / or aromatic substances, as required. Those skilled in the art will recognize that other pharmaceutical excipients are useful in the present invention.
[0207] The term "pharmaceutically acceptable salts" refers to salts derived from a variety of organic and inorganic counterions well known in the art, including, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like, and, where the molecule contains a basic functional group, includes salts of organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like.
[0208] The term "preparation" is intended to include formulations of active compounds using encapsulating materials as carriers, providing capsules in which the active ingredient is surrounded by the carrier, with or without other carriers, thereby associated with the carrier. Also included are cachets and lozenges. Tablets, powders, capsules, pills, cachets and lozenges can be used as solid dosage forms suitable for oral administration.
[0209] In some embodiments, the pharmaceutical composition comprises ibrutinib, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises idelalisib, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises fostamatinib, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises acalabrutinib, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises ONO / GS-4059, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises BGB-3111, cirumtuzumab, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises CC-292 (AVL-292), cirumutuzumab, and a pharma- ceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises R406, cirumutuzumab, and a pharma- ceutically acceptable excipient.
[0210] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 1 mg / kg and cirumutuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 1 mg / kg and cirumutuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 1 mg / kg and cirumutuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 1 mg / kg and cirumutuzumab in an amount equivalent to a dose of 5 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 1 mg / kg and cirumutuzumab in an amount equivalent to a dose of 10 mg / kg.
[0211] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 2 mg / kg and cirumutuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 2 mg / kg and cirumutuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 2 mg / kg and cirumutuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 2 mg / kg and cirumutuzumab in an amount equivalent to a dose of 5 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 2 mg / kg and cirumutuzumab in an amount equivalent to a dose of 10 mg / kg.
[0212] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 5 mg / kg and cirumutuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 5 mg / kg and cirumutuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 5 mg / kg and cirumutuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 5 mg / kg and cirumutuzumab in an amount equivalent to a dose of 5 ...10 mg / kg.
[0213] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 10 mg / kg and cirumutuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 10 mg / kg and cirumutuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 10 mg / kg and cirumutuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 10 mg / kg and cirumutuzumab in an amount equivalent to a dose of 5 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 10 mg / kg and cirumutuzumab in an amount equivalent to a dose of 10 mg / kg.
[0214] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 15 mg / kg and cirumtuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 15 mg / kg and cirumtuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 15 mg / kg and cirumtuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 15 mg / kg and cirumtuzumab in an amount equivalent to a dose of 5 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 15 mg / kg and cirumtuzumab in an amount equivalent to a dose of 10 mg / kg.
[0215] In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 420 mg and cirumtuzumab in an amount equivalent to a dose of 1 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 420 mg and cirumtuzumab in an amount equivalent to a dose of 2 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 420 mg and cirumtuzumab in an amount equivalent to a dose of 3 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 420 mg and cirumtuzumab in an amount equivalent to a dose of 5 mg / kg. In some embodiments, the pharmaceutical composition comprises ibrutinib in an amount equivalent to a dose of 420 mg and cirumtuzumab in an amount equivalent to a dose of 10 mg / kg. EXAMPLES
[0216] Signal transduction by BCR (B cell receptor) signaling is believed to play a role in the pathogenesis and / or progression of diseases, such as chronic lymphocytic leukemia (CLL). The importance of this cascade in CLL biology seems to be underscored by clinical trials showing clinical activity with small molecule kinase inhibitors intended to block BCR signaling. However, almost all inhibitors intended to block BCR signaling fail to have a complete response (CR), suggesting that other mechanisms that counteract BCR signaling may be involved in the CR of CLL following treatment with BCR signaling. Applicants have discovered that, in particular, ROR-1 (a survival signal in CLL) is induced by the inhibitor and may be a key contributor to this effect.
[0217] Receptor tyrosine kinase-like orphan receptor 1 (ROR-1) is a cancer germline antigen expressed on the cell surface of lymphoma and leukemic cells from patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but not on normal B cells or other postpartum tissues. Binding of the ligand Wnt5a to ROR-1 leads to recruitment of guanine exchange factors (GEFs) that activate Rac1 and RhoA, promoting disease-associated chemotaxis and proliferation. Targeting the BCR and ROR-1 signaling pathways with simultaneous inhibition of BTKBTK and ROR-1 has not yet been reported. The study presented here evaluated the activity of ibrutinib in combination with the novel and selective anti-ROR-1 antibody cirumutuzumab in primary CLL samples. Treatment with both a BTK inhibitor and an anti-ROR-1 antibody further reduced CLL cell viability compared to treatment with a single agent alone, and in combination induced synergistic growth inhibition due to further disrupted ligand-induced signaling, where co-targeting of these kinases would significantly enhance clinical activity.
[0218] Furthermore, the enhanced efficacy observed with anti-ROR-1 and ibrutinib combination therapy was an unexpected benefit. Specifically, this enhanced efficacy was not observed when ibrutinib was combined with an anti-CD20 antibody that exhibits cell-mediated anti-primary reactivity. In fact, ibrutinib was shown to block the activity of CD20.
[0219] [Example 1] Sirmutuzumab (UC-961) in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia overview Ibrutinib is a small molecule that reversibly inhibits Bruton's tyrosine kinase (BTK) and shows efficacy in chronic lymphocytic leukemia (CLL) patients by blocking B-cell receptor (BCR) signaling, but does not induce complete response (CR) or long-term remission. RTK-like orphan receptor-1 (ROR-1) is a receptor for Wnt5a and plays a key role in non-canonical Wnt signaling in CLL progression. In this study, applicants tested the effect of ibrutinib on Wnt5a / ROR-1 signaling-mediated activity in CLL cells. Applicants found that Wnt5a can induce Rac1 activation in ibrutinib-treated CLL cells, but ibrutinib treatment can inhibit CLL proliferation in the absence of Wnt5a, which was reversed by Wnt5a stimulation. These effects were blocked by the humanized anti-ROR-1 monoclonal antibody (mAb), cirumutuzumab (UC-961). Furthermore, combination treatment with UC-961 and ibrutinib significantly inhibited CLL growth in vitro and engraftment of ROR-1+ leukemic cells in vivo, which was more effective than either agent alone. The results of this study provide a rationale for combining UC-961 and ibrutinib as treatment for patients with CLL and other B-cell malignancies that express ROR-1.
[0220] Introduction Signaling through the B cell receptor (BCR) plays a key role in the pathogenesis and progression of CLL. Cross-linking of the BCR leads to phosphorylation of CD79a / b and the Src family kinase LYN, which then recruits and activates the tyrosine kinase Syk, triggering a cascade of downstream signaling events and enhancing B cell survival. The importance of this cascade in CLL biology seems to be underscored by the therapeutic efficacy upon small molecule inhibition of kinases such as Syk, Akt, and BTK, which are critical for BCR signaling. Ibrutinib is an inhibitor of BTK and can induce long-term clinical responses in most patients, as long as treatment is continued indefinitely. However, most patients generally achieve only partial responses (PR). Moreover, patients practically never achieve complete responses (CR) and lack detectable minimal residual disease (MRD) even after extended single agent treatment.
[0221] The inability of ibrutinib to achieve deep CR may be due to the existence of alternative survival signaling pathways that are not blocked by inhibitors of BTK. One such pathway is induced by signaling through ROR-1, a carcinoembryonic antigen expressed on CLL cells but not in normal postpartum tissues. Applicants have discovered that ROR-1 can act as a receptor for Wnt5a, which can induce non-canonical Wnt signaling that leads to activation of Rho GTPases (e.g., Rac1) and enhance proliferation and survival of leukemia cells. Activation of Rac1 by Wnt5a could be inhibited by anti-ROR-1 mAb (UC-961), a first-in-class humanized monoclonal antibody currently being evaluated in clinical trials in CLL patients.
[0222] In this study, the applicants observed Wnt5a / ROR-1 signaling in the presence of the BCR signaling inhibitor ibrutinib and investigated the combined effect of ibrutinib and the humanized anti-ROR-1 monoclonal antibody (mAb), cirumutuzumab (UC-961), for the treatment of CLL in vitro and in vivo.
[0223] result UC-961 inhibits Wnt5a-induced Rac1 activation in CLL cells in the presence of ibrutinib. Wnt5a can induce Rac1 activation in various cell types, including CLL cells. Applicants evaluated whether Wnt5a can induce Rac1 activation in ibrutinib-treated CLL cells. To this end, Applicants treated CLL cells with ibrutinib at concentrations of 0, 0.25, 0.5, or 1.0 μM for 2 hours, and then treated the cells with exogenous Wnt5a for 30 minutes. Immunoblot analysis showed that treatment with Wnt5a induced Rac1 activation, and such activation could not be blocked by ibrutinib (Figure 6A), even at a concentration of 1 μM, a concentration considered to be supraphysiological, resulting in 100% BTK occupancy, consistent with previous reports (Figure 6B). Moreover, concentrations of ibrutinib as low as 0.25 μM completely inhibited calcium flux induced by BCR engagement with anti-μ (fig. S11C) and indeed did not affect CLL cell viability ( Fig. 6D ).
[0224] The maximum concentration of ibrutinib in CLL patient plasma is about 0.5 μM. Thus, applicants treated CLL cells with 0.5 μM ibrutinib in subsequent studies. Applicants tested Wnt5a-induced Rac1 activation with or without UC-961. Applicants pretreated CLL cells with ibrutinib, UC-961, or a combination of ibrutinib and UC-961 for 2 hours, and then treated the cells with or without Wnt5a recombinant protein for 30 minutes. Ibrutinib did not inhibit Wnt5a-induced Rac1 activation, but UC-961 treatment reduced Wnt5a-induced Rac1 activation to a level comparable to that observed in CLL cells not treated with exogenous Wnt5a (Figures 1A-1B). Furthermore, the combination of UC-961 and ibrutinib also inhibited Wnt5a-induced Rac1 to basal levels (Figures 1A-1B).
[0225] Applicants investigated whether CLL cells from patients undergoing treatment with ibrutinib could be stimulated with Wnt5a. For this, blood mononuclear cells were collected from patients undergoing treatment with ibrutinib at a standard therapeutic dose of 420 mg QD. Isolated CLL cells were incubated with or without Wnt5a and / or UC-961. Western blot analysis showed that Wnt5a induced Rac1 activation in CLL cells derived from these patients, whereas incubation with UC-961 inhibited Wnt5a-induced Rac1 activation; the levels of active Rac1 were similar to those in untreated samples (Figures 1C-1D). These results indicate that ibrutinib does not inhibit Wnt5a-induced Rac1 activation.
[0226] UC-961 inhibits Wnt5a-enhanced proliferation of CLL cells in the presence of ibrutinib. Activation of Rac1-GTPase can enhance proliferation. Applicants have demonstrated that in the presence of exogenous interleukin (IL)-4 and IL-10, CD154-expressing cells (HeLa CD154) to induce proliferation of CLL cells. Addition of exogenous Wnt5a to such cultures significantly enhanced the cell division rate, estimated from the fluorescence intensity of cells labeled with carboxyfluorescein succinimidyl ester (CFSE). This effect could be inhibited by UC-961 (Figure 2A). In contrast, CLL cells cocultured with wild-type HeLa cells did not induce proliferation, even in the presence of IL-4 / 10 and / or Wnt5a (Figures 7A-7B). Applicants' results showed that Wnt5a-induced proliferation could be inhibited by UC-961 to a level comparable to that observed in cultures without Wnt5a. Treatment with ibrutinib was able to inhibit CD154-induced CLL cell proliferation. However, exogenous Wnt5a could also enhance the rate of cell division in the presence of ibrutinib (Figure 2A), which could be inhibited by UC-961 (Figure 2A). The same effect was observed using CLL cells from different patients (N=6) (Figure 2B). Collectively, these data indicate that UC-961 was able to block Wnt5a signaling without being affected by treatment with ibrutinib.
[0227] Combination of UC-961 and ibrutinib in xenografts derived from CLL patients. Applicants have demonstrated that immunodeficient Rag2 - / - Gamma c - / - CLL was implanted into the peritoneal cavity of mice to generate xenografts. Applicants tested the ability of the combination of UC-961 and ibrutinib to deplete CLL cells in such xenografts. To this end, Applicants used 1×10 UC-961 in AIM-V medium. 7Viable primary CLL cells were injected into the peritoneal cavity of each mouse. One day later, the mice were either untreated or received daily ibrutinib at a dose of 15 mg / kg by oral ingestion and / or UC-961 once at 1 mg / kg. Seven days later, CLL cells were collected by peritoneal lavage (PL) and examined by flow cytometry. The number of CLL cells calculated per PL was significantly lower in the groups of mice treated with UC-961 or ibrutinib than the number collected from control untreated mice. However, animals treated with both UC-961 and ibrutinib had significantly fewer CLL cells per PL than each of the other groups, including those treated with the single agents ibrutinib or UC-961 (Figure 3). These data indicate an additive effect of UC-961 to ibrutinib in depleting leukemic cells in this xenograft model.
[0228] UC-961 inhibits Wnt5a-enhanced Rac1 activation and proliferation of ROR-1×TCL1 leukemia cells in the presence of ibrutinib. ROR-1×TCL1 leukemia cells were isolated from ROR-1×TCL1 double transgenic mice with advanced leukemia. Applicants pretreated ROR-1×TCL1 leukemia cells with ibrutinib or UC-961 for 2 hours and then treated the cells with or without Wnt5a recombinant protein for 30 minutes. Similar to our findings with human CLL cells, Wnt5a-induced Rac1 activation could be inhibited by UC-961 but not by ibrutinib (Figures 4A-4B). The combination of UC-961 and ibrutinib also inhibited Wnt5a-induced activation of Rac1 to basal levels (Figures 4A-4B). However, Wnt5a treatment failed to induce Rac1 activation in leukemia cells derived from single transgenic TCL1 mice lacking expression of ROR-1 ( Fig. 8A ).
[0229] Again, ROR-1×TCL1 leukemia cells were cultured in HeLa CD154The addition of exogenous Wnt5a treatment significantly enhanced the cell division rate and number of cell divisions, which can be estimated from the fluorescence of cells labeled with CFSE (Figures 4C-4D). Similar to human CLL cells, ROR-1×TCL1 leukemia cells cocultured with wild-type HeLa cells did not induce proliferation, even in the presence of IL-4 / 10 and / or Wnt5a (Figure 8B). Treatment with ibrutinib was able to partially inhibit ROR-1×TCL1 leukemia cell proliferation induced by CD154. UC-961, without ibrutinib, was unable to inhibit the ability of Wnt5a to enhance ROR-1×TCL1 leukemia cell proliferation in response to CD154 and IL-4 / 10 (Figures 4C-4D). On the other hand, Wnt5a was not able to inhibit the ability of Wnt5a to enhance ROR-1×TCL1 leukemia cell proliferation in response to CD154 and IL-4 / 10 in the absence of ibrutinib (Figures 4C-4D). CD154 However, it did not enhance proliferation of ROR-1-negative TCL1- leukemia cells co-cultured with IL-4 / 10.
[0230] Combination of UC-961 and ibrutinib in mice engrafted with ROR-1 × TCL1 leukemia Applicants believe that the combination of UC-961 and ibrutinib inhibits Rag2 - / - Gamma c - / - In mice, ROR-1 × TCL1 leukemia cells (CD5 + B220 low ROR-1 + The applicants investigated the ability of Rag2 to inhibit the engraftment of ES cells. - / - Gamma c - / - For mice, 2 x 10 4ROR-1×TCL1 leukemia cells were transplanted, and the animals were then treated with ibrutinib at 15, 5, or 1.67 mg / kg daily, or with UC-961 at a single dose of 10, 3, or 1 mg / kg. After 25 days, the animals were sacrificed and the spleens were examined. Ibrutinib and UC-961 inhibited the growth of ROR-1×TCL1 leukemia cells in a dose-dependent manner. Applicants selected UC-961 at a single dose of 1 mg / kg and ibrutinib at a daily dose of 5 mg / kg for combination testing. Mice treated with UC-961 or ibrutinib alone had significantly smaller spleens than untreated littermates, and combined treatment with UC-961 and ibrutinib maximally reduced spleen size (Figure 5A). Applicants examined the proportion of ROR-1×TCL1 leukemia cells in the spleen via flow cytometry (FIG. 5B). The percentage and total number of ROR-1×TCL1 leukemia cells per spleen was significantly lower in mice treated with UC-961 or ibrutinib compared to mice that received no treatment. However, animals treated with both UC-961 and ibrutinib had significantly fewer ROR-1×TCL1 leukemia cells per spleen than each of the other groups, including those treated with the single agent ibrutinib or UC-961 (FIG. 5C).
[0231] Consideration CLL is a monoclonal, mature CD5+ / -cell-specific antigen (CD5+ / -CD5+) antigen that proliferates in tissue compartments such as lymph nodes (LNs) and bone marrow (BM). +CLL is characterized by the proliferation of B cells. Differences in tumor growth are likely the main cause of the heterogeneous clinical pathway of CLL, reflecting genetic differences between malignant lymphocytes and the activity of external signals that drive tumor growth. CLL cells depend on soluble factors present in the tumor microenvironment for cell interaction, proliferation, and survival. Among the pathways that may support the proliferation and survival of CLL in vivo, BCR signaling appears to be an important one. BTK is involved in BCR signaling and is necessary for many aspects of CLL progression. In this study, applicants showed that treatment with ibrutinib inhibited BTK 100%, inhibited IgM-induced BCR signaling (e.g., calcium flux), and reduced CD154-mediated CLL proliferation.
[0232] Cellular pathways operate more like networks than highways. Cancers use diverse pathological signaling gene regulatory mechanisms to promote their survival, proliferation, and malignant phenotype. Applicants report that ROR-1 is expressed in CLL and contributes to CLL progression. This functional study showed that Wnt5a, a ligand for ROR-1, stimulates ROR-1 to activate Rac1 in CLL cells, and that Wnt5a / ROR-1 signaling is important for CLL progression. Applicants investigated the effect of ibrutinib on the function of Wnt5a / ROR-1 signaling, which has been shown to be important for Rac1 activation and CLL proliferation. Applicants found that ibrutinib can inhibit CD154-induced CLL proliferation in the presence of exogenous IL-4 / 10, consistent with previously reported data, but not in HeLa CD154We found that co-culture with cells failed to inhibit Wnt5a-induced Rac1 activation and Wnt5a-enhanced CLL proliferation. Furthermore, Wnt-5a markedly induced Rac1 activation in patients in response to ibrutinib treatment. CLL patients showed primary resistance to ibrutinib due to resistant clones of CLL cells. This may be explained by the fact that ibrutinib does not block Wnt5a-induced signaling, which is important for CLL biology, especially in the microenvironment of LN and BM. It has been reported that ibrutinib blocks FcγR-mediated calcium signaling and cytokine production, but has no effect on Rac activation, which is responsible for actin polymerization and phagocytosis.
[0233] Combination therapy is often required to effectively treat many tumors because there are multiple redundant (i.e., alternative) pathways that can be activated in response to inhibition of one pathway and cause drug resistance and clinical relapse. Researchers have been involved in combination therapy with ibrutinib with other drugs for the treatment of leukemia. An increase in Bcl-2 protein was also observed, along with a decrease in Mcl-1 and Bcl-XL, suggesting a survival mechanism for ibrutinib-treated CLL cells. The combination of ibrutinib with a Bcl-2 inhibitor (ABT-199) showed synergistic effects on growth inhibition and apoptosis in mantle cell lymphoma cells by perturbing the BTK and Bcl-2 pathways. BTK and PI3K separately regulate BCR signaling, and combination therapy with ibrutinib and a PI3K inhibitor (idelalisib) causes more pronounced recruitment of MCL and CLL cells from the niche that promotes growth and survival. Furthermore, the combination study of ibrutinib and anti-CD20 mAbs showed that ibrutinib substantially reduced CD20 expression on CLL cells, and subsequently reduced complement-mediated cell death. This negative interaction between ibrutinib and anti-CD20 mAbs may reduce the efficacy of the combination therapy. All these studies indicated that it is important to identify possible interactions or crosstalks between BCR signaling and alternative signaling when performing combination therapy with ibrutinib.
[0234] Applicants have now shown that UC-961 exhibits significant inhibitory activity in Wnt5a-induced Rac1 activation, thereby inhibiting Wnt5a-enhanced CLL proliferation. Furthermore, administration of a combination of UC-961 and ibrutinib significantly inhibited recipient Rag2 expression due to an additive effect greater than that caused by each agent alone. - / - Gamma c - / - It eradicated leukemia cells in mice.
[0235] UC-961 and ibrutinib enhance each other's effects. As a result, the combination therapy is expected to not only reduce the proliferation rate in the niche that promotes its growth, but also to result in a more significant reduction in the recruitment of CLL cells from there. Since BTK and ROR-1 do not need to be fully occupied when the combination is used, the effect may be stronger and longer-lasting in terms of drug clearance and protein turnover. Furthermore, lower doses may be given, which would be beneficial for the efficacy / toxicity ratio. However, the main importance is that targeting more than one key component of the pathway may overcome the original treatment resistance and overcome or prevent the subsequent (single agent) treatment resistance. For example, UC-961 may still be beneficial in ibrutinib-treated patients with mutations in the ibrutinib binding site on BTK, mutations in additional molecules in the BTK axis (e.g., PLCγ2), and SF3B1 mutations, which have been identified to be associated with poor prognosis.
[0236] Taken together, Applicants' use of UC-961 in in vitro and in vivo systems with CLL or ROR-1 x TCL1 leukemia cells supports the efficacy of UC-961 as a therapeutic drug and merits further investigation in combination with ibrutinib for CLL and other ROR-1 expressing B cell malignancies possibly dependent on active BCR signaling and / or the tumor microenvironment.
[0237] method Cell and sample preparation CLL specimen Blood samples were collected from CLL patients at the University of California San Diego Moores Cancer Center. PBMCs were isolated by density centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences) and suspended in 90% fetal bovine serum (FBS) (Omega Scientific) and 10% DMSO (Sigma-Aldrich) for viable storage in liquid nitrogen. Over 95% of CD19 + CD5 + Samples containing CLL cells were used throughout this study without further purification.
[0238] Ibrutinib occupancy assay CLL cells were treated with increasing concentrations of ibrutinib (0, 0.25, 0.5 or 1 μM) for 1 h. Cells were then washed with phosphate-buffered saline and stored at -80°C until BTK occupancy assays were performed as described above. BTK occupancy was compared using GraphPad Prism version 6.0 (GraphPad, San Diego, CA).
[0239] Calcium mobilization assay CLL cells were incubated with 0, 0.25, 0.5, or 1.0 μM ibrutinib for 30 min and then incubated with Ca in Hanks Balanced Salt Solution (HBSS). 2+ and Mg 2+ The cells were loaded with 2 mM Fluo-4AM (Molecular Probes) lacking IgG. For stimulation with anti-human IgM F(ab)2, cells were maintained at 37° C. Calcium release was monitored by flow cytometry analysis as described.
[0240] Cell proliferation assay Proliferation assays of primary CLL or ROR-1 x TCL1 leukemia cells were performed as described. Leukemia cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Life Technologies) and cultured in 24-well trays in complete RPMI-1640 medium supplemented with 5 ng / mL recombinant human interleukin (IL)-4 (R&D Systems) and 15 ng / mL recombinant human IL-10 (R&D Systems). CD154 On top of the cell layer (8000Rad; 80Gray), CLL / HeLa CD154 At a cell ratio of 15:1, 1.5 × 10 6 Cells were seeded at 100 μg / ml per well. Wnt5a (200 ng / ml, R&D Systems) or UC-961 (10 μg / ml) were added as indicated in the text. CFSE-labeled CLL cells were analyzed by flow cytometry. Modfit LT software (version 3.0, Verity Software House) was used for analysis of cell proliferation as previously described.
[0241] Rac1 activation assay Rac1 activation assay reagents were purchased from Cytoskeleton and used according to the manufacturer's instructions. Briefly, GTP-bound active Rac1 was pulled down using PAK-PBD beads, followed by immunoblot analysis. Total Rac1 was assessed using immunoblots of whole cell lysates. The integrated optical density (IOD) of the bands was assessed by densitometry and analyzed using Gel-Pro Analyzer 4.0 software (Media Cybernetics, MD).
[0242] Immunoblot analysis Western blot analysis was performed as described above. Equal amounts of total protein from each sample were fractionated by SDS-PAGE and blotted onto polyvinylidene difluoride membranes. Western blot analysis was performed using a primary mAb specific for Rac1, which was detected with a secondary antibody conjugated to horseradish peroxidase (Cell Signaling Technology).
[0243] Xenograft studies derived from human CLL patients Rag2, 6-8 weeks old - / - Gamma c - / - Mice (originally obtained from Catriona Jamieson, University of California, San Diego) were housed in a laminar flow cabinet under specific pathogen-free conditions and fed ad libitum. Applicants cultured 2×10 7 Viable primary CLL cells were injected into the peritoneal cavity of each mouse. The following day, UC-961 was injected once intraperitoneally at 1 mg / kg, and ibrutinib was administered daily by oral intake at 15 mg / kg. After 7 days, peritoneal lavage fluid (PL) was extracted by injecting a total volume of 12 mL of Dulbecco's PBS into the peritoneal cavity. The total recovery of PL cells was determined by using Guava counting. Cells were then blocked with mouse and human Fc blockers for 30 minutes at 4°C, stained with various human cell surface markers (e.g., CD19, CD5, CD45), and then subjected to flow cytometry analysis. Applicants calculated the number of CLL cells in each PL by multiplying the percentage of CLL cells in the PL by the total PL cell count. Residual leukemic cells from mice treated with human IgG were set as baseline at 100%. Each treatment group contained at least 6 mice and data are expressed as mean ± SEM.
[0244] ROR-1×TCL1 leukemia adoptive cell transfer study Applicants have identified an immunodeficient Rag2 - / - Gamma c - / -The anti-leukemic activity of the combination of UC-961 and ibrutinib was evaluated in mice. ROR-1 × TCL1 leukemic B cells (CD5 + B220 low ROR-1 + ) were isolated from the spleen, enriched by density gradient centrifugation, suspended in sterile PBS, and - / - Gamma c - / - Recipient mice received 2 x 10 4 The cells were injected intravenously. Samples used for transplantation were demonstrated to be more than 95% leukemic B cells by flow cytometry. For dose-dependent treatment with UC-961, recipient mice were either untreated or intravenously injected once on day 1 with 10 mg / kg, 3 mg / kg, and 1 mg / kg UC-961. For dose-dependent treatment with ibrutinib, recipient mice were either untreated or orally administered 15 mg / kg, 5 mg / kg, and 1.67 mg / kg ibrutinib daily starting on day 1. For combination therapy, recipient mice were either untreated or intravenously injected once with 1 mg / kg UC-961 and / or daily with 5 mg / kg ibrutinib starting on day 1. All mice were sacrificed on day 25, and single cell suspensions of splenocytes were cleared from red blood cells by hypotonic lysis in ammonium chloride-potassium (ACK) lysis solution, washed, suspended in 2% (wt / vol) BSA (Sigma) in PBS (pH=7.4), and stained for surface expression of CD3 (17A2), CD5 (53-7.3), B220 (RA3-6B2), and ROR-1 (4A5) using optimized concentrations of chromogenic dye-conjugated mAbs. Cells were examined by four-color multiparameter flow cytometry using a dual-laser FACSCalibur (BD), and data were analyzed using FlowJo software (TreeStar). CD5 out of total lymphocytes was stained for surface expression using optimized concentrations of chromogenic dye-conjugated mAbs. + B220 low ROR-1 + The percentage of cells was determined by flow cytometry, and the total number of leukemic cells per spleen was calculated by multiplying this number by the total spleen cell count.
[0245] statistics For data sets satisfying the conditions for normal distribution, data are presented as mean ± SEM, as determined by the Kolmogorov-Smirnov test. Statistical significance of differences between means was assessed by one-way ANOVA with Tukey's multiple comparison test. P values less than 0.05 were considered significant. Analysis of significance was performed using GraphPad Prism 6.0 (GraphPad Software Inc.).
[0246] [Example 2] Combination studies CLL cells were treated with different BCR inhibitors and examined for ROR-1 expression. ROR-1 expression was significantly induced after BCR inhibitor treatment. Applicants used immunodeficient Rag2 / common gamma-light chain knockout mice (Rag2 - / - Gamma c - / - CLL cells with increased ROR-1 expression induced by BCR signaling inhibitors were cultured in the peritoneal cavity of mice (Fig. 1b) and then treated with control Ig, anti-ROR-1 antibody, ibrutinib, or a combination of anti-ROR-1 antibody and ibrutinib. CLL cells were more sensitive to treatment with the combination of anti-ROR-1 antibody and ibrutinib than to treatment with anti-ROR-1 antibody or ibrutinib alone. The ability of the combination of anti-ROR-1 antibody and ibrutinib to inhibit adoptive cell transfer of murine leukemia cells expressing human-ROR-1 was tested in immunodeficient recipient mice. Six RAG2 mice were cultured in the peritoneal cavity of mice (Fig. 1b) and then treated with control Ig, anti-ROR-1 antibody, ibrutinib, or a combination of anti-ROR-1 antibody and ibrutinib. CLL cells were more sensitive to treatment with the combination of anti-ROR-1 antibody and ibrutinib than to treatment with anti-ROR-1 antibody or ibrutinib alone. The ability of the combination of anti-ROR-1 antibody and ibrutinib to inhibit adoptive cell transfer of murine leukemia cells expressing human-ROR-1 was tested in immunodeficient recipient mice. - / - Gamma c - / - Mice were intravenously injected with 1 mg / kg of humanized anti-human ROR-1 mAb UC-961. Two hours later, all mice received 1x10 4 CD5 + B220 lo Human ROR-1 +Mice were injected intravenously with leukemia cells. Daily treatment with ibrutinib was initiated the day after leukemia xenografts. Compared to control animals, animals treated with single agent or combination treatment with anti-ROR-1 antibody and ibrutinib showed a greater than 90% reduction in leukemia cells in the spleen, the main organ where malignant tumor cells accumulate.
[0247] CLL cells were treated with different BCR inhibitors and examined for ROR-1 expression, as shown in Figure 9. ROR-1 expression was significantly induced after BCR inhibitor treatment.
[0248] As shown in FIG. 10, Applicants generated immunodeficient Rag2 / common gamma-light chain knockout mice (Rag2 - / - Gamma c - / - CLL cells with increased ROR-1 expression induced by a BCR signaling inhibitor were cultured in the peritoneal cavity of mice treated with control Ig, anti-ROR-1 antibody, ibrutinib, or a combination of anti-ROR-1 antibody and ibrutinib. CLL cells were more sensitive to treatment with the combination of anti-ROR-1 antibody and ibrutinib than to treatment with either anti-ROR-1 antibody or ibrutinib alone.
[0249] As shown in Figure 11, Rag2 - / - Gamma c - / - Mice were incubated with 1x10 4 CD5 + B220 lo Human ROR-1 + Mice were injected intravenously with leukemia cells and then treated the following day with control Ig, anti-ROR-1 antibody, ibrutinib, or a combination of anti-ROR-1 antibody and ibrutinib. Combined treatment with anti-ROR-1 antibody and ibrutinib significantly reduced leukemia cells in the spleen, the main organ where malignant tumor cells accumulate, compared with treatment with anti-ROR-1 antibody or ibrutinib alone.
[0250] [Example 3] Sirmutuzumab inhibits Wnt5a-induced Rac1 activation in ibrutinib-treated chronic lymphocytic leukemia overview Signaling through the B cell receptor (BCR) plays a key role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical efficacy of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that can block BCR signaling. However, ibrutinib fails to induce complete response (CR) or long-term remission without continued treatment, suggesting that alternative pathways also contribute to CLL growth / survival independent of BCR signaling. ROR-1 is a receptor for Wnt5a, which can promote activation of Rac1 and enhance the proliferation and survival of CLL cells. In this study, applicants found that CLL cells from patients treated with ibrutinib activated Rac1. Furthermore, Wnt5a could induce Rac1 activation and enhance proliferation of CLL cells treated with ibrutinib at a concentration effective to completely inhibit BTK and BCR signaling. Wnt5a-induced Rac1 activation could be blocked by the anti-ROR-1 mAb cirumtuzumab (UC-961). Applicants found that treatment with cirumtuzumab and ibrutinib was significantly more effective than treatment with either agent alone in depleting leukemia cells in vivo. This study demonstrated that cirumtuzumab is a potent anti-ROR-1 inhibitor in CLL or other ROR-1 + We demonstrate that it may enhance the activity of ibrutinib in the treatment of patients with B-cell malignancies.
[0251] Introduction CLL cells depend on soluble factors present in the tumor microenvironment for cell interaction, growth and survival. Among the pathways that may support CLL growth and survival in vivo, BCR signaling plays a key role. Cross-linking of the BCR leads to phosphorylation of CD79α / β and the Src family kinase LYN, leading to recruitment and activation of the tyrosine kinase Syk, triggering a cascade of downstream signaling events and enhancing B cell survival. The importance of this cascade in CLL biology seems to be underscored by the clinical activity of small molecule inhibitors of intracellular kinases that play key roles in BCR signaling, such as SYK, phosphinositide 3-kinase (PI3K), or Bruton's tyrosine kinase (BTK). Ibrutinib is a small molecule inhibitor of BTK that has proven highly effective in treating CLL patients. However, despite its excellent clinical activity, ibrutinib generally fails to eradicate disease or induce durable responses in the absence of continuous treatment.
[0252] The inability of ibrutinib to induce a complete response may be due to alternative survival signaling pathways that are not blocked by inhibitors of BTK. One such pathway is induced by signaling through ROR-1, a carcinoembryonic antigen expressed on CLL cells but not in normal postpartum tissues. Applicants have discovered that ROR-1 can serve as a receptor for Wnt5a, which can induce non-canonical Wnt signaling that leads to activation of Rho GTPases (e.g., Rac1) and enhance proliferation and survival of leukemia cells. Activation of Rac1 by Wnt5a could be inhibited by cirumtuzumab (UC-961), an anti-ROR-1 mAb, a first-in-class humanized monoclonal antibody currently being evaluated in clinical trials in CLL patients.
[0253] In this study, the applicants observed whether Wnt5a / ROR-1 signaling was affected by treatment with ibrutinib and investigated the activity of ibrutinib and cirumutuzumab against CLL cells in vitro and in vivo.
[0254] Materials and Methods Blood samples and animals Blood samples were collected from CLL patients at the University of California San Diego Moores Cancer Center who met diagnostic and immunophenotypic criteria for common B-cell CLL and provided written informed consent in accordance with the Declaration of Helsinki and the Institutional Review Board (IRB) of the University of California San Diego (IRB approval number 080918). PBMCs were isolated as described. All experiments with mice were performed in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals and study protocols approved by the University of California San Diego. All mice were age- and sex-matched.
[0255] BTK occupancy assay CLL cells were treated with increasing concentrations of ibrutinib (0, 0.25, 0.5 or 1 μM) for 1 h. Cells were then washed with phosphate-buffered saline and stored at -80°C until BTK occupancy assays were performed as described above. BTK occupancy was compared using GraphPad Prism version 6.0 (GraphPad, San Diego, CA).
[0256] Calcium mobilization assay CLL cells were incubated with 0, 0.25, 0.5, or 1.0 μM ibrutinib for 30 min and then incubated with Ca in Hanks Balanced Salt Solution (HBSS). 2+and Mg 2+ The cells were loaded with 2 mM Fluo-4AM (Molecular Probes) lacking IgG. For stimulation with anti-human IgM F(ab)2, cells were maintained at 37° C. Calcium release was monitored by flow cytometry analysis as described.
[0257] Rac1 activation assay Reagents for the Rac1 activation assay were prepared in our laboratory as previously described. Rac1 depletion and immunoblot analysis were performed as described.
[0258] Cell proliferation assay Applicants performed leukemia cell proliferation assays as previously described. For these analyses, Applicants used characteristic light scatter and the ability to exclude PI to identify viable CD5+ cells. + CD19 + Gating was performed on cells (FIGS. 18A-18B).
[0259] Cell cycle analysis Leukemia cells (1x10 7 ) were suspended in 100 μl of PBS and fixed overnight at 4° C. by adding 1 ml of cold ethanol. The cells were spun at 700×g for 2 min and washed twice with PBS containing 1% BSA. The pelleted cells were then suspended in 500 μl of PBS containing 1% BSA and 1 μl of RNase (100 mg / ml). PNase was added to digest the RNA. PI solution (0.5 mg / ml in 38 mM sodium citrate, pH 7.0), 1 μl of boiled RNase A (100 mg / ml) and PI staining solution (0.5 mg / ml in 38 mM sodium citrate, pH 7.0; 60 μl) were added to the cells and incubated for 1 h at room temperature in the dark. Immediately after, the cells were analyzed by flow cytometry using a FACSArray (Becton Dickinson) and the data were analyzed using FlowJo software (Tree Star Inc.).
[0260] Xenografts derived from CLL patients Rag2, 6-8 weeks old - / - Gamma c - / - Mice (originally obtained from Catriona Jamieson, University of California, San Diego) were housed in a laminar flow cabinet under specific pathogen-free conditions and fed ad libitum. Applicants cultured 2×10 7 Viable primary CLL cells were injected into the peritoneal cavity of each mouse. The following day, 1 mg / kg cirumutuzumab was injected intraperitoneally once and ibrutinib was administered by oral intake at 15 mg / kg daily. After 7 days, peritoneal lavage fluid (PL) was extracted by injecting a total volume of 12 mL of Dulbecco's PBS into the peritoneal cavity. The total recovery of PL cells was determined by using Guava counting. Cells were then blocked with mouse and human Fc blockers for 30 minutes at 4°C, stained with various human cell surface markers (e.g., CD19, CD5, CD45), and then subjected to flow cytometry analysis. Applicants calculated the number of CLL cells in each PL by multiplying the percentage of CLL cells in the PL by the total PL cell count. Residual leukemic cells from mice treated with human IgG were set as baseline at 100%. Each treatment group contained at least 5 mice and data are expressed as mean±SEM.
[0261] ROR-1×TCL1 leukemia adoptive cell transfer study As previously described, the applicants have - / - Gamma c - / - Alternatively, the anti-leukemic activity of the combination of cirumutuzumab and ibrutinib was evaluated in immunocompetent ROR-1-transgenic mice.
[0262] statistical analysis Data are presented as mean ± SEM. Normal distribution of the data sets was determined by Kolmogorov-Smirnov test. Statistical significance of differences between means was assessed by one-way ANOVA with Tukey's multiple comparison test. Applicants calculated the level of significance using GraphPad Prism 6.0 (GraphPad Software Inc.) and the statistical methods described in the text. p ≦ 0.05 was considered significant.
[0263] result Ibrutinib fails to inhibit Wnt5a-induced Rac1 activation in CLL. Applicants examined blood mononuclear cells from patients receiving ibrutinib at a standard dose of 420 mg per day. As shown for CLL cells from patients not receiving ibrutinib, freshly isolated CLL cells had activated Rac1, which decreased over time in cultures in serum-free medium unless exogenous Wnt5a was provided (Figures 12A-12B). Furthermore, CLL cells from ibrutinib-treated patients were incubated with or without Wnt5a and / or cirumtuzumab. Immunoblot analysis showed that Wnt5a induced Rac1 activation in CLL cells from all patients tested, while treatment with cirumtuzumab inhibited Wnt5a-induced Rac1 activation (Figures 12C-12D). These results indicate that treatment with ibrutinib does not inhibit ROR-1-dependent Wnt5a-induced Rac1 activation.
[0264] Applicants investigated whether treatment of CLL cells in vitro with ibrutinib could inhibit Wnt5a-induced Rac1 activation in CLL. To this end, Applicants incubated CLL cells collected from untreated patients with ibrutinib at concentrations of 0, 0.25, 0.5 or 1.0 μM for 2 hours, and then treated the cells with exogenous Wnt5a for 30 minutes. Immunoblot analysis showed that ibrutinib was unable to block Wnt5a-induced Rac1 activation, even at an ibrutinib concentration of 1 μM (Figure 6A). This concentration is in large excess of the amount required to achieve 100% occupancy of BTK and inhibition of BTK activity (Figure 6B). On the other hand, Applicants showed that ibrutinib inhibited anti-IgM-induced calcium flux (Figure 6C) at concentrations as low as 0.25 μM without dramatically affecting CLL cell viability (Figure 6D).
[0265] The peak plasma concentration of ibrutinib in patients treated with this drug is about 0.5 μM, a concentration that can affect 100% occupancy and inhibition of BTK. Therefore, ibrutinib was used at 0.5 μM for subsequent studies. Applicants tested Wnt5a-induced Rac1 activation with or without ibrutinib and / or cirumtuzumab. CLL cells were cultured with ibrutinib, cirumtuzumab, or both ibrutinib and cirumtuzumab for 2 hours and then stimulated with exogenous Wnt5a for 30 minutes. For comparison, cells derived from the same CLL samples were cultured in parallel without Wnt5a. Treatment of CLL cells with Wnt5a induced activation of Rac1 to a significantly higher level than CLL cells not treated with Wnt5a (Figures 12E-12F). Treatment with sirumtuzumab, but not ibrutinib, was able to inhibit Wnt5a-induced Rac1 activation in CLL cells (Figures 12E-12F). As expected, ibrutinib did not block the ability of sirumtuzumab to inhibit Wnt5a-induced Rac1 activation (Figures 12E-12F).
[0266] Sirmutuzumab inhibits Wnt5a-enhanced proliferation of ibrutinib-treated CLL cells. Activation of Rac1-GTPase can enhance proliferation, whereas loss of Rac1 attenuates hematopoietic cell growth. Applicants have demonstrated that CD154-expressing HeLa cells (HeLa CD154 The proliferation of CLL cells was induced by co-culturing the leukemia cells with recombinant interleukin (IL)-4 and IL-10. CD154 Addition of exogenous Wnt5a to co-cultures of cells with IL-4 / 10 significantly enhanced the division rate of CLL cells. Treatment of CLL cells with silmutuzumab, but not ibrutinib, was able to block the Wnt5a-enhanced proliferation of CLL cells (Figure 13A). The same effect was observed for CLL cells from different patients (n=6) (Figure 13B). IL4 / 10 and / or Wnt5a alone were unable to induce CLL cell proliferation (Figures 18A-18B). Furthermore, cell cycle analysis of leukemia cells permeabilized with propidium iodide (PI) showed that Wnt5a enhanced leukemia cell function stimulated by CD154 in S / G2 / M (Figures 13C-13D). The ability of Wnt5a to increase the proportion of cells in S / G2 / M could be inhibited by treatment with sirumtuzumab, but not with ibrutinib (Figures 13C-13D).
[0267] Activity of cirumtuzumab and / or ibrutinib in xenografts derived from CLL patients. Applicants have demonstrated that immunodeficient Rag2 - / - Gamma c - / - Mice were implanted with CLL cells into the peritoneal cavity to determine whether treatment with ibrutinib and / or cirumutuzumab would deplete CLL cells in vivo. To this end, Applicants used 1×10 7Viable primary CLL cells were injected into the peritoneal cavity of each mouse. One day later, the mice were either untreated or received ibrutinib at a dose of 15 mg / kg by oral ingestion daily and / or cirumtuzumab at 1 mg / kg once by intraperitoneal injection. Seven days later, CLL cells were collected by peritoneal lavage (PL), and the percentage of CLL cells in the collected peritoneal cells was examined by flow cytometry (Figure 14A). The percentage and total number of CLL cells in PL were significantly lower in mice treated with cirumtuzumab or ibrutinib than in mice that did not receive any treatment. However, significantly lower CLL cells were found in the PL of mice treated with cirumtuzumab and ibrutinib than in the PL of mice treated with either drug alone (Figure 14B).
[0268] Sirmutuzumab, but not ibrutinib, inhibits Wnt5a-enhanced Rac1 activation and proliferation of ROR-1×TCL1 leukemia cells. + The ROR-1×TCL1 double transgenic mice were isolated from leukemia-progressing leukemia. Applicants pretreated ROR-1×TCL1 leukemia cells with ibrutinib or cirumutuzumab for 2 hours and then cultured the cells with or without Wnt5a for 30 minutes. Similar to the findings with human CLL cells, Wnt5a-induced Rac1 activation could be inhibited by cirumutuzumab but not by ibrutinib (FIGS. 15A-15B). The combination of cirumutuzumab and ibrutinib also inhibited Wnt5a-induced activation of Rac1 to the level observed in untreated cells (FIGS. 15A-15B). However, Wnt5a treatment failed to induce Rac1 activation in leukemia-progressing single transgenic TCL1 mice leukemia-progressing leukemia cells lacking expression of ROR-1 (FIG. 7C).
[0269] Again, applicants investigated the proliferation of ROR-1×TCL1 leukemia cells in the presence of recombinant IL-4 / 10, in comparison with HeLa CD154Exogenous Wnt5a significantly increased the percentage of cell division (Figure 15C). When human CLL cells were used, Wnt5a and / or IL-4 / 10 alone did not increase the ROR-1 proliferation rate in ROR-1 × TCL1 transgenic mice. + Wnt5a was unable to induce proliferation of leukemia cells (Fig. 15C), indicating a dependency of CD154 for this effect. CD154 Wnt5a did not enhance the proliferation of ROR-1-negative TCL1- leukemia cells co-cultured with CD154 and IL-4 / 10 (Fig. 21A), indicating the dependency of this effect on ROR-1. Treatment with ibrutinib failed to inhibit the ability of Wnt5a to enhance ROR-1 x TCL1 leukemia cell proliferation induced by CD154. Meanwhile, cirumutuzumab blocked the ability of Wnt5a to enhance ROR-1 x TCL1 leukemia cell proliferation in response to CD154 and IL-4 / 10 (Fig. 15C).
[0270] As shown for human CLL cells, cell cycle analysis of ROR-1×TCL1 leukemia cells permeabilized with PI showed that Wnt5a could increase the fraction of ROR-1+ leukemia cells stimulated by CD154 in S / G2 / M (Figures 19A-19B). Furthermore, the ability of Wnt5a to increase the fraction of ROR-1+ leukemia cells in S / G2 / M could be inhibited by treatment with cirumutuzumab, but not by treatment with ibrutinib (Figures 19A-19B).
[0271] Treatment of immune-deficient mice implanted with ROR-1×TCL1 leukemia with cirumab and / or ibrutinib. Applicants have demonstrated that Rag2 - / - Gamma c - / - We investigated the ability of cirumutuzumab and / or ibrutinib to inhibit engraftment of ROR-1xTCL1 leukemia cells in mice. Applicants administered 2x10 4ROR-1×TCL1 leukemia cells were transplanted, and then daily ibrutinib was administered by oral ingestion at 15, 5, 1.67 mg / kg, or cirumutuzumab was administered once by intravenous injection at 1, 3, or 10 mg / kg. After 25 days, the animals were sacrificed and the spleen of each animal was examined. Ibrutinib (FIG. 20A) or cirumutuzumab (FIG. 20B) reduced the number of splenic leukemia cells in a dose-dependent manner. Applicants selected cirumutuzumab at a dose of 1 mg / kg and ibrutinib at a daily dose of 5 mg / kg for combination testing. Transplanted mice treated with cirumutuzumab or ibrutinib alone had significantly smaller spleens than transplanted animals that did not receive any treatment, but mice treated with the combination of cirumutuzumab and ibrutinib showed the greatest reduction in spleen size (FIG. 16A). Furthermore, the average percentage and number of leukemic cells in the spleen was significantly lower in mice treated with cirumtuzumab or ibrutinib compared to untreated transplanted mice (Figures 16B-16C). However, transplanted animals treated with cirumtuzumab and ibrutinib had significantly lower percentages and numbers of leukemic cells per spleen than all other groups (Figures 16B-16C).
[0272] Treatment of immunocompetent mice transplanted with ROR-1×TCL1 leukemia with cirumtuzumab and / or ibrutinib. Applicants have demonstrated that cirumtuzumab and / or ibrutinib inhibited the expression of ROR...
Claims
1. 1. A method of treating cancer in a subject in need of treatment, the method comprising administering to the subject therapeutically effective amounts of a Bruton's tyrosine kinase (BTK) antagonist and a tyrosine kinase-like orphan receptor 1 (ROR-1) antagonist.
2. 2. The method of claim 1, wherein the BTK antagonist is a small molecule.
3. 2. The method of claim 1, wherein the BTK antagonist is ibrutinib, idelalisib, fostamatinib, acalabrutinib, ONO / GS-4059, BGB-3111, or CC-292 (AVL-292).
4. 2. The method of claim 1, wherein the BTK antagonist is ibrutinib.
5. The method of claim 1, wherein the ROR-1 antagonist is an antibody or a small molecule.
6. The method of claim 1, wherein the ROR-1 antagonist is an anti-ROR-1 antibody.
7. the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region; the humanized heavy chain variable region comprises the sequence shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; The method of claim 5, wherein the humanized light chain variable region comprises the sequences shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:
6.
8. The method of claim 5 , wherein the antibody is cirumutuzumab.
9. the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region; the humanized heavy chain variable region comprises the sequence shown in SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9; 6. The method of claim 5, wherein the humanized light chain variable region comprises the sequences shown in SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:
12.
10. 10. The method of claim 1, wherein the BTK antagonist and the ROR-1 antagonist are administered in a combined synergistic amount.
11. 2. The method of claim 1, wherein the BTK antagonist and the ROR-1 antagonist are administered simultaneously or sequentially.
12. 2. The method of claim 1, wherein the ROR-1 antagonist is administered at a first time point and the BTK antagonist is administered at a second time point, the first time point being prior to the second time point.
13. 10. The method of claim 1, wherein the BTK antagonist and the ROR-1 antagonist are mixed prior to administration.
14. 13. The method of claim 1, wherein the BTK antagonist is administered in an amount of about 1 mg / kg, 2 mg / kg, 5 mg / kg, 10 mg / kg, or 15 mg / kg.
15. 13. The method of claim 1, wherein the BTK antagonist is administered in an amount of about 5 mg / kg.
16. 13. The method of claim 1, wherein the BTK antagonist is administered in an amount of about 420 mg.
17. 10. The method of claim 1, wherein the ROR-1 antagonist is administered in an amount of about 1 mg / kg, 2 mg / kg, 3 mg / kg, 5 mg / kg, or 10 mg / kg.
18. 10. The method of claim 1, wherein the ROR-1 antagonist is administered in an amount of about 2 mg / kg.
19. 2. The method of claim 1, wherein the BTK antagonist is administered in an amount of about 5 mg / kg and the ROR-1 antagonist is administered at about 2 mg / kg.
20. 2. The method of claim 1, wherein the BTK antagonist is administered in an amount of about 5 mg / kg and the ROR-1 antagonist is administered at about 1 mg / kg.
21. 10. The method of claim 1, wherein the BTK antagonist is administered daily for at least 14 days.
22. 10. The method of claim 1, wherein the BTK antagonist is administered daily for about 28 days.
23. 10. The method of claim 1, wherein the ROR-1 antagonist is administered once for about 28 days.
24. 13. The method of claim 1, wherein the BTK antagonist is administered intravenously.
25. 10. The method of claim 1, wherein the ROR-1 antagonist is administered intravenously.
26. The method of claim 1 , wherein the subject is a mammal.
27. The method of claim 1 , wherein the subject is a human.
28. 2. The method of claim 1, wherein the cancer is lymphoma, leukemia, myeloma, AML, B-ALL, T-ALL, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, head and neck cancer, uterine cancer, adenocarcinoma, or adrenal gland cancer.
29. 2. The method of claim 1, wherein the cancer is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, peripheral B-cell lymphoma, Burkitt's lymphoma, or B-cell leukemia.
30. A pharmaceutical composition comprising a BTK antagonist, a ROR-1 antagonist, and a pharma- ceutically acceptable excipient.
31. 1. A pharmaceutical composition comprising a BTK antagonist, an anti-ROR-1 antibody, and a pharma- ceutical acceptable excipient, wherein said BTK antagonist and said anti-ROR-1 antibody are present in a combined synergistic amount, and said combined synergistic amount is effective to treat cancer in a subject in need of such treatment.
32. 31. The pharmaceutical composition of claim 30, wherein the BTK antagonist is a small molecule.
33. The pharmaceutical composition of claim 30, wherein the BTK antagonist is ibrutinib, idelalisib, fostamatinib, acalabrutinib, ONO / GS-4059, BGB-3111, or CC-292 (AVL-292).
34. 31. The pharmaceutical composition of claim 30, wherein the BTK antagonist is ibrutinib.
35. The pharmaceutical composition of claim 30, wherein the ROR-1 antagonist is an antibody or a small molecule.
36. The pharmaceutical composition of claim 30, wherein the ROR-1 antagonist is an anti-ROR-1 antibody.
37. the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region; the humanized heavy chain variable region comprises the sequence shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; 36. The pharmaceutical composition of claim 35, wherein the humanized light chain variable region comprises the sequences shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:
6.
38. 36. The pharmaceutical composition of claim 35, wherein the antibody is cirumutuzumab.
39. the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region; the humanized heavy chain variable region comprises the sequence shown in SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9; 36. The pharmaceutical composition of claim 35, wherein the humanized light chain variable region comprises the sequence shown in SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
